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ABSTRACT
REGULATION OF VANCOMYCIN RESISTANCE
AND STRESS RESPONSE BY THE MSAABCR
OPERON IN STAPHYLOCOCCUS AUREUS
by Dhritiman Samanta
August 2015
Staphylococcus aureus is the predominant cause of public health problems around
the world. Vancomycin has been an important antibiotic against Methicillin Resistant
Staphylococcus aureus (MRSA) infections. However, Vancomycin Intermediate S.
aureus (VISA) strains have been reported. These strains are characterized by thick cell
walls, reduced autolytic rate, reduced PBP4 activity, and increased amount of D-Ala-DAla termini in the cell wall. In this study, we show that the msaABCR operon regulates
vancomycin resistance in two clinical VISA strains. Deletion of the msaABCR operon in
strains Mu50 and HIP6297 resulted in a significant decrease in the minimum inhibitory
concentration (MIC) for vancomycin. Transmission Electron Microscopic analysis
showed a 50% decrease in the cell wall thickness in the mutants relative to wild types.
The msaABCR mutant of Mu50 but not HIP6297 showed a 3-fold up-regulation of pbp4.
Up-regulation of pbp4 was confirmed by fluorescent penicillin–binding assay, which
showed that the mutant has a 6-fold higher amount of PBP4 protein relative to wild type.
Mu50 msaABCR mutant also showed a 6-fold down-regulation of stress response
regulator sigB. On the other hand, the msaABCR mutant of HIP6297 showed a 4-fold
down-regulation of mprF. Collectively, my data show that the msaABCR is required for
maintaining the thickness of cell wall and vancomycin resistance in two clinical VISA
ii

strains Mu50 and HIP6297; however, the mechanism and regulation by the msaABCR
operon in the genetic level are strain dependent.
Staphylococcus aureus is also the predominant cause of bacteremia worldwide.
The health hazard burden caused by this species is severely exacerbated by worldwide
dissemination of clones resistant to beta-lactam antibiotics in hospitals and communities.
The distribution of MRSA clones is dynamic and tends to be geographically unique. The
purpose of the second part of my study is to determine the molecular characteristics and
antibiotic resistance properties of the MRSA isolates causing bacteremia in a major
hospital in south Mississippi, USA. This study allows us to associate specific clonal types
with bacteremia isolates and detect outbreak by any particular type in south Mississippi.
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CHAPTER I
INTRODUCTION
The Biology of Staphylococcus aureus
Staphylococcus aureus (S. aureus) is a Gram - positive coccus bacterium
belonging to the phylum Firmicutes, class Bacilli, and order Bacillales. This coagulase
positive coccus, measuring about 0.7 – 1.2 µm in diameter, is much studied because of its
clinical importance to human. Although S. aureus normally resides in the nose, throat,
armpit, groin, and intestinal tract of healthy individuals, when introduced into a wound or
skin incision, cause infections. According to the Center for Disease Control and
Prevention (CDC), S. aureus is the most common cause of hospital-acquired infections
causing 80,461 invasive MRSA infections including 11,285 deaths in USA. Tremendous
amount of resources have been used to understand the molecular basis of its virulence
and evolutionary success using modern technology. An in depth understanding of its
global regulatory network is necessary to fully decipher its array of virulence factors and
to devise mechanism to control it.
The term “staphylococcus” was synthesized from the Greek word “staphyle,”
which means bunch of grapes and the term “coccus” meaning grain or berry, because of
its clustered appearance under microscope. Robert Koch, in 1878 first identified that
abscesses are caused by Gram-positive cocci. Later in 1884, Rosenbach classified species
of staphylococci depending on their capability of producing pigments, where more
virulent species formed golden colonies whereas less pathogenic ones formed white
colonies. Coagulase testing later proved to be a better classification of staphylococci than
pigment formation. In clinic, a positive coagulase test confirms the identity of S. aureus.
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Figure 1.1. A representative image of S. aureus under microscope. Characteristic
clumping behavior is evident in this figure. (Photo Credit: Janice Haney Carr, Center for
Disease Control and Prevention)
S. aureus grows most rapidly under aerobic conditions and in the presence of
carbon-di-oxide. However, S. aureus is also capable of surviving in environments with
very low concentrations of oxygen as well, such as within a biofilm (1). It is versatile in
terms of tolerating extreme conditions. For example it can tolerate high amounts of salt in
growth medium (7.5 – 10% of Sodium Chloride) (2) and a wide pH range (4.8 – 9.4).
S. aureus colonizes human body in early years of life and is carried throughout
the life. 30% of United States population carry S. aureus in the nasal passage (3, 4). It
adheres to nasal mucosal surface with the help of several virulence factors such as surface
protein adhesins, fibronectin – binding protein, and clumping factor (5-8). A large variety
of proteins and carbohydrates expressed on the cell surface enables S. aureus to bind to a
number of host factors such as epithelial cells, endothelial cells, platelets, and host
intercellular matrix proteins (9). Penicillin, once was used to treat S. aureus infections.
However, as S. aureus got resistant to it, methicillin, a penicillin derivative was
introduced. S. aureus, however acquired resistance against methicillin quickly. Rise of
Methicillin Resistant S. aureus (MRSA) has caused a widespread problem in public
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health worldwide. MRSA causes about 1,20,000 hospitalizations and more than 1 billion
dollars healthcare costs in the U.S.. Initially, MRSA strains were largely confined to
hospitals and were referred to as hospital-acquired MRSA (HA-MRSA), causing
treatment difficulties, especially in patients with prior exposure to antibiotics. During the
past two decades, S. aureus infections have been worsened by the emergence of
community-acquired MRSA (CA-MRSA). The United States, in particular has been
facing an epidemic caused by CA-MRSA isolates. CA-MRSA isolates are clinically
significant because they can also cause severe health issues in individuals who are
apparently healthy and have never been exposed to any predisposing risk factors. It is
imperative that new therapeutic solutions are found for this rapidly evolving pathogen.
Staphylococcus aureus is a multifaceted pathogen that causes a wide array of
infections ranging from simple skin abscesses to more complex and life threatening
conditions like endocarditis and osteomyelitis. Other serious conditions caused by S.
aureus include S. aureus bacteremia (SAB), S. aureus infective endocarditis (SAIE),
surgical site infections, device related infections (catheters, implants etc.), skin and soft
tissue infections (SSTIs), spine and brain abscesses, ocular diseases, staphylococcal
pneumonia, urinary tract infections, toxic shock syndrome, and toxin mediated
syndromes. S. aureus is able to cause these infections by successfully utilizing an array of
virulence factors. These factors are often redundant and/or variable across different
strains, making it even harder to formulate effective prophylactic or immunological
therapies.
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A

B

Figure 1.2. A. Endocarditis and B. Osteomyelitis. Photo credit: Center for Disease
Control and Prevention)
Antibiotic Resistance in Staphylococcus aureus
Treatment of S. aureus has become more difficult attributable to the profuse
increase in prevalence of MRSA strains in the last few decades. Particularly, CA-MRSA
strains are of great concern because of their capability of causing wide variety of
infections, high growth rate, and causing diseases in people without any risk factors. CAMRSA strains cause skin and soft tissue infections, which spreads from skin to skin
contact with infected individuals. Interestingly, CA-MRSA is resistant to only β-lactams
and only a few other classes of antibiotics, however, HA-MRSA is resistant to multiple
types of antibiotics (10). The antibiotic resistance profile of MRSA strains is partly due to
the presence of resistance genes that are located in a mobile genetic element called
Staphylococcal cassette chromosome mec (SCCmec). The methicillin resistance of S.
aureus is the result of the presence of the mecA gene, which encodes a 78-kDa penicillinbinding protein (PBP2a or PBP2′). S. aureus possesses four types of penicillin binding
proteins, which are essential enzymes for synthesis of cell wall. The β-lactam antibiotics
such as penicillin and methicillin bind to PBP2 and inhibits cell wall synthesis process.
PBP2a, produced by mecA gene in MRSA strains has a lower affinity for the β-lactam
antibiotics. As a result, even in the presence of these antibiotics, the peptidoglycan
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synthesis is not disrupted and the bacterium survives (11, 12). The mecA gene is housed
within the mec operon along with the regulatory genes mecI and mecR1 (11). Since the
first detection of the SCCmec element from N315 in 1999, multiple mec types have been
identified because of the hypervariability of SCCmec elements. Nine SCCmec types (I–
VIII and VT) have been detected to date. These are distinguished by the ccr gene complex
which helps in excision and insertion of SCCmec elements (13-15). Clones of unique
SCCmec types have driven the epidemic of MRSA strins worldwide. For example,
SCCmec type I was first discovered in the United Kingdom in 1961 and spread around
the world during the ’60s. Following that, in 1982, SCCmec type II was first identified in
Japan also spread worldwide. During the 1990s SCCmec type IV caused a global
epidemic.

6

Figure 1.3. Different types of SCCmec elements distinguished by ccr gene complex and
mec complex type. (David and Daum, Clin. Microbiol. Review, 2010)
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CHAPTER II
BACKGROUND RELEVANT TO THIS STUDY
Cell Wall Synthesis and Vancomycin Resistance in
Staphylococcus aureus
The glycopeptide antibiotic vancomycin has been used to successfully treat
MRSA infections. Increasing prevalence of MRSA resulted in excessive use of
vancomycin thereby increasing the selective pressure, which leads to the development of
resistance. The first clinical strain that was reported to be vancomycin resistant was
Mu50, which was isolated in 1997 from a Japanese male patient who had been under
vancomycin treatment for prolonged period of time before the strain was isolated.
Subsequently, there have been reports of similar strains being isolated from other parts of
the world.
The mechanism of intermediate vancomycin resistance seems novel. Many of the
vancomycin non–susceptible strains tested have been found negative for van gene
complex that confer vancomycin resistance in enterococci. Although there are phenotypic
variations among the vancomycin non-susceptible strains from different parts of the
world, the most common characteristic feature is a very thick cell wall. Increase in cell
wall synthesis has been reported from both the clinical and laboratory-generated strains.
Vancomycin targets the D-ala-D-ala subunits of the peptidoglycan leading to cell
death by inhibiting cell wall crosslinking. It is important to understand the cell wall
synthesis in order to fully understand the action of vancomycin and how the bacterium
resists it. Walsh et al (16) described the process as following. S. aureus cell wall is
composed of peptidoglycan, which is a polysaccharide matrix composed of unbranched

8
β-1,4-linked chains containing alternating subunits of N-acetylglucosamine (GlcNAc)
and N-acetylmuramic acid (MurNac). Biosynthesis of glucosamine-1-phosphate from
glucose and/or glucosamine initiates the process of peptidoglycan synthesis. Pyrimidine
UDP is then linked to glucosamine-1-phosphate to produce UDP-N-acetyl-glucosamine
(UDP-GlcNAc). A second molecule of UDP-GlcNAc combines with phosphoenol
pyruvate, which is produced from glucose in glycolysis to form UDP-N-acetyl-muramic
acid (UDP-MurNAc). An L-alanine is then linked to the UDP-MurNAc residue followed
by D-glutamate, L-lysine, and D-alanyl-D-alnine to form the UDP-MurNAc
pentapeptide. It is then transferred to the C55-undecaprenylphosphate to form LIPID-I of
the cytoplasmic membrane peptidoglycan transporter. Next step is the formation of
pentaglycine side chain on the L-lysine component. The D-glutamate component is then
amidated to D-glutamine using an L-glutamine, which acts as a NH4+ donor. This
complex is then transferred to the outside of the cell. It is then joined to the nascent
peptidoglycan chain by the activity of transglycosylase enzymes, which links the moieties
Glc-NAc-MurNAc –pentapeptide-pentaglycine. Transpeptidase enzymes then join the
pentaglycine chain of one monomer to the penultimate D-Ala residue of the pentapeptide
of the next peptidoglycan chain, releasing the last D-Ala residue. This cleavage of the last
D-Ala residue is a key step to the cell wall crosslinking process. Although theoretically
all D-Ala-D-Ala residues should be digested in the process, approximately 20% of them
remain intact. Vancomycin binds to the D-Ala-D-ala residue of the peptidoglycan
precursor UDP-MurNAc-pentapeptide and inhibit transpeptidation and nascent
peptidoglycan synthesis. Bacterium dies because of incomplete cell wall.
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Vancomycin non-susceptible strains have been found to possess an increased cell
wall synthesis coupled with reduced crosslinks in the peptidoglycan. It is proposed that
reduced levels of peptidoglycan crosslinking leads to an increased amount of intact DAla-D-ala side chains to which vancomycin can bind. The main location of cell wall
synthesis in S. aureus is the tip of the division septum of a bacterium and not the entire
plasma membrane surface (17). Therefore, in order for vancomycin to prevent cell wall
synthesis, it would have to diffuse through the cell wall to the tip of the division septum,
which is approximately a 25-nm path (18). The D-Ala-D-Ala-vancomycin complex in the
outer edges of the peptidoglycan are likely to sterically hinder the other vancomycin
molecules preventing its diffusion from the environment to the cell’s active site, which is
the tip of the division septum in the cytoplasmic membrane (19, 20). This enables
vancomycin non-susceptible strains to continue synthesizing peptidoglycan and to
survive in a vancomycin-containing environment.
Stress response regulator genes, such as sigma B, have been found to regulate
antibiotic resistance in S. aureus. Cold shock is one of the stress factors that bacteria may
encounter. Designated cold shock proteins (CSPs) respond to the environment and induce
the expression of necessary genes to keep bacterial cells alive. MsaB protein (previously
called Cold shock protein A) of S. aureus is predicted to contain a cold shock DNA
binding domain (CSD) and bears homology to E. coli and B. subtilis cold shock proteins
(CSPs). Bacteria respond to abrupt decrease in temperature by changing the protein
expression patterns (21). Although expression of most cellular proteins decrease during
the cold stress, expression of cold shock proteins reaches its peak at this time. One of the
first proteins described to express under cold shock is the E. coli cold shock protein CspA
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(22). Although most CSPs are found to be expressed during cold shock, CspE and CspC
are found to express constitutively at normal growth conditions at 37°C. Moreover, the
constitutively expressed CSPs were thought to be regulating two major stress response
proteins of E. coli RpoS and UspA (23). In the last chapter of my dissertation, I
investigated the role of msaB gene and MsaB protein in survival of S. aureus in stress
environment.

Figure 2.1. Model of mechanism of action of vancomycin that binds to the lipid II of
peptidoglycan precursor and blocks the downstream pathway of cell-wall biosynthesis.
(Figure courtesy: Natividad Ruiz, PNAS 2008)
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CHAPTER III
THE msaABCR OPERON REGULATES RESISTANCE IN
VANCOMYCIN-INTERMEDIATE Staphylococcus aureus STRAINS
Abstract
Vancomycin-intermediate Staphylococcus aureus (VISA) strains poses a serious
public health threat. The molecular mechanism responsible for this resistance is not yet
completely understood. In this part of my study, I investigate the role of the newly
discovered msaABCR operon in establishing vancomycin resistance in three clinical
VISA strains, Mu50, HIP6297, and LIM2. Deletion of the msaABCR operon resulted in a
significant decrease in the vancomycin MIC (from 6.25 to 1.56 µg/mL) and a significant
reduction of cell wall thickness in all three VISA strains. Mutants exhibited a
significantly slower growth in medium containing vancomycin, at a concentration greater
than 2 µg/ml, compared with the wild-type strain. Mutants also revealed significantly less
capability to bind vancomycin molecules in medium compared to wild type. From this
study, I conclude that the msaABCR operon in S. aureus strains contributes to resistance
against vancomycin and cell wall synthesis.
Introduction
Staphylococcus aureus is an important public health pathogen in both community
and healthcare settings. S. aureus can cause wide range of infections that can be
superficial (e.g., skin and soft tissue infections) or life threatening (e.g., toxic shock,
endocarditis, and septicemia) (24). One of the key attributes of S. aureus as a pathogen is
the acquisition of antibiotic resistance, as evidenced by the rise and widespread
prevalence of methicillin-resistant S. aureus strains (MRSA). The recent emergence of
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community-acquired MRSA strains that are more virulent compared to other strains has
worsened the situation (25, 26). Indeed, since the 1990s, MRSA strains have been
responsible for one third of all S. aureus infections worldwide (27). Vancomycin, a
glycopeptide antibiotic has been the drug of choice to treat MRSA infections for a long
time (24). However, vancomycin non-susceptibility in S. aureus is becoming increasingly
prevalent.
Vancomycin-resistant S. aureus strains have been categorized into two major
groups depending on their level of resistance, as measured by the minimum inhibitory
concentration (MIC). According to the Clinical Laboratory Standards Institute (CLSI), S.
aureus strains are considered sensitive if their MIC of vancomycin is less than or equal to
2 µg/ml. Strains are called vancomycin-intermediate S. aureus (VISA) if their MIC
ranges from 4 to 8 µg/ml, while strains that show a vancomycin MIC higher than 16
µg/ml are classified as vancomycin-resistant S. aureus (VRSA). The prevalence of the
VRSA strains is very low compared to VISA strains, which are more frequently
encountered (28)
First report of VISA strains came from a hospital in Japan in 1997 and since then
these strains have emerged as a serious threat to public health owing to the extensive use
of vancomycin in healthcare settings (29). Since then, several MRSA strains with
intermediate-level resistance to vancomycin have been isolated from all over the world
(30-38). In clinical settings, patients infected by VISA strains tend to have several comorbidities like diabetes mellitus, end-stage renal disease, or cancer; and usually have
been found to have received a prolonged course of vancomycin prior to isolation and
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detection of VISA. Additionally, infections also can occur in biomedical devices such as
catheters and transplants and they do not respond well to vancomycin treatment (16).
Despite a number of studies performed by several people, the mechanism of
vancomycin intermediate resistance is not completely understood. As mentioned before,
vancomycin targets the cell wall and inhibits its synthesis by attaching to D-Ala-D-Ala
residues of pentapeptide sidechain of undecaprenylphosphate-MurNAc-pentapeptide.
Multiple genetic and biochemical mechanisms have been found to play together to
establish the VISA phenotypes. These include: a thickened cell wall (39), reduced
autolytic activity (40), increased proportion of non-amidated muropeptides (41), and
reduced cross-linking between murein monomers caused by down-regulation of
penicillin-binding protein 4 (PBP4) (42, 43), which ultimately leads to an accumulation
of D-Ala-D-Ala pseudo-targets in the cell wall (20). Moreover, several genes have been
found to be altered in expression in VISA strains. These include genes like atl (major
autolysin), lytM (peptidoglycan hydrolase) (40), sceD (transglycosylase) (44), mprF
(lysyl-phosphatidyl glycerol) (45), dltA (teichoic acid biosynthesis regulator), sigB (4649), ddh (50, 51), tcaA (52), and two-component systems graSR, vraSR, and walKR (53).
Yet, we do not fully understand how S. aureus strains avert the effects of vancomycin.
However, from all these studies, it is clear that resistance to vancomycin is significantly
more complex than what we have thought about it so far.
Previously, our lab has identified and characterized the msaABCR operon and
shown that it positively regulates expression of a global regulator gene sarA,
development of biofilm, and virulence of S. aureus strains(54-56). The msaABCR operon
is a four gene operon consisting of msaA (SA1235), msaB (SA1234), msaC (SA1233)
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which are all in same orientation, and newly discovered msaR antisense RNA which is in
opposite orientation (56). One of the most important phenotypes observed in the
msaABCR operon mutant was increased triton-X–induced autolysis rate (Figure 3.1). A
reduced rate of autolysis has been previously correlated with vancomycin-intermediate
resistance (40, 57). Although the mechanism unclear, some studies have suggested that
reduced autolysis indeed leads to resistance against multiple cell-wall active antibiotics
(58). Also, inactivation of the sarA has been shown to lead to a decrease in the
vancomycin MIC of laboratory-derived VISA strains (59). These findings led me to
investigate the role of the msaABCR operon in the establishment of vancomycin
intermediate resistance phenotype of S. aureus, and indeed our results show that the
msaABCR operon contributes significantly vancomycin resistance in three different
clinical VISA strains, Mu50, HIP6297 and LIM2.
Materials and Methods
Bacterial strains and culture conditions
Wild type and mutant strains of S. aureus are listed in Table 3.1. Escherichia coli
strain TOP10 (Life Technologies, New York, USA) was used for molecular cloning
experiments. Luria-Bertani medium was used for E. coli culture. Brain-heart infusion
(BHI) broth and agar were routinely used for culturing all VISA strains unless otherwise
mentioned. Tryptic soy broth and agar were used for culturing S. aureus strain RN4220.
For maintaining plasmids, appropriate antibiotics were added to the media at a
concentration of 100 µg/mL of ampicillin for E. coli and 10 µg/mL of chloramphenicol
for S. aureus.
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Generation of the deletion mutants and complementation
All plasmids and primers used in this study are listed in Table 3.2. Isogenic
deletion mutants of the msaABCR operon were generated in the VISA Mu50, HIP6297,
and LIM2 strains using the plasmid pKOR1, as described previously (60). Briefly,
approximately 1 kb of sequence up- and downstream of the operon region was PCR
amplified with operon deletion primers (Operon del 1 through 4). The PCR products were
digested with restriction enzyme BamHI and ligated. The ligation product was amplified
again with the terminal AttB-containing operon deletion primers (Operon del 1 and 4)
and recombined into pKOR1 using the BP Clonase Kit (Life Technologies) resulting in
pKOR1∆msaABCR. This plasmid was introduced into S. aureus RN4220 by
electroporation. The constructs were subsequently transduced into strains Mu50,
HIP6297 and LIM2 using bacteriophage φ. Mutagenesis was performed using the method
described by Bae and Schneewind, 2006 (60). The mutation was confirmed by PCR using
terminal primers.
For trans-complementation, a low copy number plasmid pCN34 was used (61).
To replace the kanamycin (aphA-3) selection marker of pCN34 with a chloramphenicol
marker, the cat gene was PCR amplified from pHV1249 (62) using the primers Cm-F and
Cm-R to generate an ApaI–XhoI fragment, which was then cloned into pCN34 resulting
in plasmid pCN34(Cmr). A 1.7-kb BamHI and EcoRI fragment was then PCR amplified
using the primers Comp-F1 and Comp-R1 from the genomic DNA of S. aureus strain
Mu50/HIP6297/LIM2 and cloned into pCN34(Cmr) generating the pCN34(Cmr)–
msaABCR operon. This plasmid was introduced into S. aureus strain RN4220 by
electroporation and subsequently transduced into the deletion mutant strains.
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Complemented strains were always maintained in media containing 10 µg/mL of
chloramphenicol.
Triton X-100 induced autolysis
Autolysis assay was performed as described by Mani et al, 1993 (63). Briefly,
overnight cultures were normalized to OD600 = 0.05 in BHI containing 1M NaCl. Cells
were harvested when they reach OD600 = 0.7, resuspended in autolysis buffer (Tris-HCl
pH=7.5, 0.05% triton X-100) and incubated in 37°C. OD600 was recorded each hour.
Vancomycin susceptibility assay
Antimicrobial susceptibility of all strains was measured in triplicate by the broth
microdilution method according to the CLSI guidelines (64). Mueller-Hinton broth
supplemented with 2% NaCl (CSMHB) was used for all broth microdilution experiments.
Antimicrobial containing wells were inoculated with 5 × 105 CFU/mL (65). After
overnight incubation at 35°C, wells were analyzed for visible bacterial growth as
exhibited by turbidity. The lowest concentration of vancomycin that prevented bacterial
growth was considered to be the MIC.
Growth curve
An aliquot of fresh bacterial culture was diluted to about 1 × 105 CFU/mL in 25
mL of fresh BHI broth and grown at 37°C with shaking. The optical density was
measured at 600 nm at time intervals. To analyze the growth defect of the msaABCR
operon mutants in vancomycin containing media, BHI supplemented with vancomycin at
a concentration of 1, 2, and 3 µg/mL was used. For replenishment of the medium in
experiments plotting prolonged growth curves, vancomycin at a concentration of 4
µg/mL was added every 6 h.
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Population analysis profile
Population analysis helps to determine how many cells within a given number of
cells are resistant to a range of concentrations of a particular antibiotic (39). Overnight
cultures of S. aureus strains Mu50, HIP6297, and their respective mutant strains were
diluted to 10–4 and 10–6 and 100 µL of each dilution were plated onto BHI agar plates
containing various concentration of vancomycin. Plates were incubated for 48 h at 37°C,
and CFUs were plotted in a logarithmic scale against the vancomycin concentration.
Transmission electron microscopy
Preparation and examination of S. aureus cells by transmission electron
microscopy were performed by the method described previously (66). Briefly,
exponentially growing cells were fixed in 2% glutaraldehyde in 0.1 M sodium phosphate
buffer and treated with 1% osmium tetroxide for 2 h at 4°C. Cells were dehydrated, and
embedded in low viscosity embedding media (Electron Microscopy Sciences). Ultra-thin
sections were stained with uranyl acetate and lead acetate. Cell wall thicknesses were
measured using photographic images at a ×30,000 final magnification. Fifteen cells of
each strain with approximately equatorial cut surfaces were measured and results were
expressed as the mean value ± standard deviation (SD). Statistical analysis was
performed using the MedCalc software (MedCalc V13, www.medcalc.org). P value less
than 0.05 was considered significant.
Vancomycin binding assay
The degree of binding of vancomycin molecules to the cell wall of wild-type
strains and their respective msaABCR operon deletion mutants was determined using a
dot blotting technique. Specifically, overnight cultures were diluted to OD600 = 0.05 in
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BHI medium containing no antibiotics. When the cells reached the mid log phase,
vancomycin was added at a concentration of 4 µg/mL to the culture. After 1 h, 500 µL of
culture was collected and centrifuged to pellet the cells. Then, 10 µL of the supernatant
was loaded onto a nitrocellulose membrane and air-dried. The membrane was then
blocked with non-fat skimmed milk, incubated with an anti-vancomycin primary
antibody, HRP-conjugated secondary antibody, and developed with SuperSignal® West
Pico Chemiluminescent substrate (Thermo Scientific, Rockford, Illinois, USA). The
intensity of the signal was measured using the ImageJ software (67)
RNA extraction, reverse transcription, and qRT-PCR
An aliquot of an overnight culture was normalized to OD600 = 0.05 and grown to
exponential phase. At this time, a dose of 4 µg/mL of vancomycin was added to the
culture. A control culture was maintained where no vancomycin was added (“none”
condition). Cells were grown for 1 h and harvested by centrifugation. The bacterial pellet
was treated with RNAprotectTM Bacteria Reagent (Qiagen, Valencia, CA, USA) and
stored at −80°C. RNA from the pellet was isolated using the RNeasy® mini kit (Qiagen)
and dissolved in DEPC-treated H2O. RNA quality was analyzed by determining the
A260/280 ratio using a nanodrop spectrophotometer (Thermo). Reverse transcription was
carried out from 1000 ng of RNA using the iScriptTM cDNA synthesis kit (Bio-Rad
Laboratories, Hercules, CA, USA) according to the manufacturer’s instructions. All realtime PCRs were performed in triplicate. The primers used for real-time PCR are listed in
Table 3.2. The fold change in gene expression was calculated using the formula 2-∆∆ct
(68), using the gyrA gene as an internal control. Fold change values were statistically
analyzed by the independent sample t test using MedCalc software.
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Absolute quantification of the sigB transcript
Absolute quantification of the sigB transcript was performed by the method
previously described by Chini et al. 2007 (69). Briefly, the sigB and gyrA genes were
amplified from chromosomal DNA using primers external to the primers used for qRTPCR. These amplicons were purified, and their concentrations were measured using a
nanodrop spectrophotometer. The corresponding concentration was converted to copies
per microliter by a previously described method (70). Tenfold serial dilutions (range 102–
106) of these amplicons were used as templates for qRT-PCR. Standard curves were
generated by plotting Ct values against the log of the copy numbers (Log Starting
Quantity, SQ). Starting quantities of “unknown” samples (cDNA of wild type and
mutant) were calculated by plotting their respective Ct values on the standard curve. Copy
numbers were measured by raising 10 to the power of the SQ (10SQ). Copy numbers of
sigB were normalized to that of gyrA and plotted. The process was repeated in triplicate
independently.
Membrane purification and PBP detection
For the detection of PBPs, membranes were prepared from wild-type and
msaABCR mutant strains following the method described by Sieradzki et al. 1999 (36),
with some modifications. Briefly, cells were grown to the late exponential phase,
harvested, and washed once with wash buffer (50 mM Tris, 150 mM NaCl, 5 mM MgCl2,
pH 7.5), resuspended in the same buffer with 0.5 mM phenylmethylsulfonyl fluoride and
10 mM β-mercaptoethanol. Cells were then treated with lysostaphin (100 µg/mL), DNase
(20 µg/mL), and RNase (10 µg/mL) for 30 min on ice followed by sonication. Broken
cells along with membranes were harvested by centrifugation at 110,000 × g for 40 min
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at 4°C, and washed with 50 mM phosphate buffer, pH 7. Membranes were solubilized in
2% Triton X-100. Protein concentrations were measured using the BCA protein assay kit
(Pierce) and a standard curve prepared from serial dilutions of bovine serum albumin.
PBPs were detected using a method described by Atilano et al. 2010 (71), with
some modifications. Briefly, 10 µg of membrane protein were mixed with 100 µM of
Bocillin-FL (Life Technologies) and incubated for 10 min at 30°C. The reaction was
stopped by the addition of 5× SDS-PAGE sample buffer. Samples were separated on a 4–
20% gradient gel and labeled proteins were detected using a Bio-Rad Versadoc. The gel
pictures were analyzed and quantified using the ImageJ software.
Results and Discussion
Deletion of the msaABCR operon increased susceptibility to vancomycin in three VISA
strains
Several studies have demonstrated that global regulators such as sarA and sigB
are involved in vancomycin resistance (59, 72); however, the mechanism of regulation is
not yet understood (47, 73). Because msaABCR is a positive regulator of sarA and a
negative regulator of autolysis, and as mentioned earlier, both the expression of sarA and
a decreased rate of autolysis have been shown to be important for the VISA phenotype,
we attempted to understand the effect of the msaABCR operon on vancomycin resistance
in VISA strains.
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Figure 3.1. Triton X-100 induced autolysis assay shows msaABCR mutants lyse in a
faster rate than the respective wild types
We deleted the msaABCR operon in three different clinical VISA strains, Mu50
(SCCmec II, ST 5) and HIP6297 (SCCmec II, ST5) and LIM2 (SCCmec I, ST247).
Mu50 is a clinical VISA strain isolated in 1997 from pus of a Japanese male child with a
post-surgery infection who was unresponsive to vancomycin treatment (29). This isolate
has a vancomycin MIC of 8 µg/mL (29), a thick cell wall relative to its sensitive parent
strain (41), reduced autolytic rates (40), reduced cell-wall cross-linking (74), and an
increased number of penta-peptide side chains (41). HIP6297 is also a clinical VISA
strain that was isolated from the blood of a 79-year-old male patient who had renal
disease and bacteremia at a hospital in New York, USA (36). It has a vancomycin MIC of
8 µg/mL and a thick cell wall (36). LIM2, another clinical VISA strain was isolated from
a 2-year old girl, in a hospital in France, who had an MRSA infection but was
unresponsive to vancomycin treatment (75).
Deletion of the msaABCR operon resulted in a significant decrease in vancomycin
resistance in all three VISA strains as showed by their MICs. Specifically, the MIC of all
three strains reduced from an intermediate resistance level of 6.25 µg/mL to a susceptible
level of 1.56 µg/mL (Table 3.3). Trans-complementation with the msaABCR operon
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cloned in pCN34 plasmid into the deletion mutants, caused an increase in MIC to 3.125
µg/mL confirming that the msaABCR operon was indeed responsible for the decrease in
their MIC (Table 3.3). It is noteworthy here that, although the MIC of the complemented
strains was not exactly in the wild type VISA range (4–8 µg/mL vancomycin), still it was
higher than the sensitive range which is 2–4 µg/mL of vancomycin. A vancomycin
sensitive strain N315, which is genetically related to strain Mu50 (76) was used as a
control in this study. As expected, deletion of the msaABCR operon in N315 did not
further reduce the vancomycin MIC. These results, taken together, show that the
msaABCR operon is essential for vancomycin resistance in VISA strains of different
genetic backgrounds.
One of the hallmarks of VISA strains is the significant change in the growth rate
relative to their sensitive counterparts (41). We measured the growth rates of the deletion
mutants at different vancomycin concentrations (1, 2, and 3 µg/mL). We found that wildtype strains displayed a steady growth rate and reached a stationary phase after 6 h at all
three concentrations of vancomycin, whereas the three mutant strains did not show any
growth after 6 h at a vancomycin concentration of 2 µg/mL or higher (Figure 3.2).
Interestingly, all the mutants showed growth after a 20-h lag period unless the medium
was replenished with vancomycin (Figure 3.3). This observation supports previous
findings by Cui et al. 2000 (41), and confirms the increased susceptibility of the
msaABCR operon mutant to vancomycin.
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Figure 3.2. Growth curves of wild types Mu50, HIP6297 and LIM2 and their
corresponding msaABCR deletion mutants in plain media and in different concentrations
of vancomycin (1, 2, and 3 µg/ml). Axes are converted to log scales.
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Figure 3.3. An elongated growth curve of wild type Mu50, HIP6297, and LIM2 and their
respective msaABCR operon deletion mutants in medium containing 4 µg/ml vancomycin
or medium replenished with 4 µg/ml vancomycin every 6 hours.
To further characterize the population of the deletion mutants with regard to
vancomycin resistance, we evaluated the homogeneity of the cells using a population
analysis profile (Figure 3.4) (39). With wild-type strain Mu50, 1010 cells/mL were
resistant to vancomycin at concentrations up to 3 µg/mL and 107 cells/mL were resistant
to a vancomycin concentration of 4 µg/mL. This indicated a small degree of
heterogeneity in resistance. However, with the Mu50 msaABCR operon mutant, 109
cells/mL were resistant to a vancomycin concentration of 1 µg/mL but no cells were
resistant to a vancomycin concentration higher than 1 µg/mL. This indicated that the
msaABCR operon mutant had a homogenously sensitive population structure with regard
to vancomycin. Likewise, in the case of HIP6297, 1010 cells/mL were resistant to 4
µg/mL of vancomycin and 109 cells/mL were resistant to 5 µg/mL of vancomycin. The
msaABCR operon mutant however possessed 109 resistant cells per mL in the presence of
3 µg/mL vancomycin and no resistant cells at higher concentrations. Wild type LIM2
maintained 1010 cells/ml up to 5 µg/mL vancomycin, whereas its msaABCR mutant
maintained 108 cells/ml only up to 2 µg/mL vancomycin. These results indicated that
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mutation of the msaABCR operon led to a population of cells that are homogenously
sensitive to vancomycin. These results also suggested that the msaABCR operon is a
regulator of resistance to vancomycin. Population analysis revealed that both of the
mutants are homogenously sensitive to vancomycin. Indeed, the msaABCR deletion
mutants did not show any resistant subpopulations in the presence of vancomycin at
concentrations greater than 3 µg/mL.

Figure 3.4. Population Analysis Profile of the wild types Mu50, HIP6297 and LIM2 and
their corresponding msaABCR operon deletion mutants.
This phenotype is of significance to the clinical treatment of VISA infections because
some VISA strains, such as Mu50, have been shown to maintain a resistant subpopulation
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to vancomycin. Indeed, Cui et al. 2003 (39) demonstrated that passage of strain Mu50
through a drug-free medium (35 days) led to a drop in the vancomycin MIC from 8
µg/mL to 2 µg/mL. However, population analysis of the passage-derived strain revealed a
resistant subpopulation that was able to grow in the presence of up to 8 µg/mL of
vancomycin (39). Such VISA strains have been defined as hetero-VISA (h-VISA) and
present a treatment challenge. They are difficult to treat because of the rise of resistant
subpopulations during treatment with vancomycin. For instance, the hetero-VISA strain
Mu3, that is isogenic to Mu50, was isolated from a Japanese male patient who was
unresponsive to vancomycin treatment. While Mu3 was initially characterized as
susceptible to vancomycin (MIC = 2 µg/mL) according to CLSI criteria (77), when it was
grown in the presence of a high concentration of vancomycin (2–9 µg/mL), it produced
resistant subclones with a MIC of 6–8 µg/mL (comparable to Mu50) at a frequency of 1
in 106. This is relevant to patients infected with h-VISA strains, where peak tissue
concentrations of vancomycin can be from 2 to 5 µg/mL depending on the dosage and
frequency of treatment (78). These studies show that the rise of a resistant subpopulation
is likely; however, the mechanism that leads to this is not yet understood. The absence of
resistant subpopulations in the msaABCR operon deletion mutants is therefore very
interesting and suggests a role of the operon in this process. Targeting regulators such as
the msaABCR operon, which eliminate h-VISA, could therefore be potentially beneficial
in developing new treatments for VISA infections.
Previously, sarA and sigB inactivation in laboratory-derived vancomycin
resistant/intermediate strains also resulted in a decrease in the vancomycin MIC. Singh et
al. 2003 (72) demonstrated that a sigB deletion mutant of the laboratory-derived strain
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13136p−m+V20 had a vancomycin MIC of 4–6 µg/mL after population analysis compared
with the wild-type strain, which had a vancomycin MIC of 12–14 µg/mL. The population
analysis profile of the mutant strain displayed a homogenously sensitive population
structure. Similarly, in the study by Lamichane-Khadka et al. 2009 (40), the sarA
insertion mutant of BB270V15 showed an MIC of 3 µg/mL in agar dilution analysis while
the wild type showed a vancomycin MIC of 8 µg/mL. In the population analysis profile,
the mutant displayed a homogenously sensitive population structure. These findings
support our hypothesis that mutation of major global regulators could have a profound
effect on vancomycin resistance of VISA strains and may render the strains
homogenously sensitive to vancomycin, which in turn could be clinically beneficial.
The msaABCR operon regulates cell wall morphology
Vancomycin is an inhibitor of cell wall synthesis in S. aureus and other Grampositive bacteria. It binds to the D-Ala-D-Ala residue of the pentapeptide sidechain of
undecaprenylphosphate-MurNAc-pentapeptide, a cell wall precursor, and forms a stable
non-covalent complex. As a result, this complex cannot be used in the biosynthesis of the
cell wall (79). VISA strains, including Mu50 and HIP6297, have thick cell walls relative
to their sensitive counterparts (36, 39, 41, 66, 80, 81). Cui et al. 2003 (39) showed that
cell wall thickening is the most consistent feature of vancomycin intermediate and
resistant strains. They also showed a positive correlation between the thickness of the cell
wall and vancomycin MIC in a study of 48 S. aureus strains including VISA and VRSA
strains.
We examined cell wall thickness of the msaABCR operon mutants using
transmission electron microscopy. Both mutants showed a significant decrease (50%) in
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cell wall thickness and a smoother texture relative to their wild-type strains (Table 3.4,
Figure 3.5 a-b). These results suggest that the msaABCR operon plays a role in cell wall
synthesis and contributes to cell wall thickness in VISA strains.

Figure 3.5(a). Transmission Electron Micrograph of cell walls of wild type Mu50 (A),
Mu50∆msaABCR (B), complemented mutants (C), and independent sample t-test of cell
wall thicknesses of all three strains (D). nm: nanometer; ns: non-significant. ***:
p<0.0001
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Figure 3.5(b). Transmission Electron Micrograph of cell walls of wild type HIP6297 (A),
HIP6297∆msaABCR (B), complemented mutants (C), and independent sample t-test of
cell wall thicknesses of all three strains (D). nm: nanometer, ***: p<0.0001
The main location of cell wall synthesis in S. aureus has been shown to be the tip
of the division septum of a bacterium and not the entire plasma membrane surface (17).
Therefore, for vancomycin to prevent cell wall synthesis, it would have to diffuse through
the cell wall to the tip of the division septum, which is approximately a 25-nm path (18).
Pfeltz et al. (2000) proposed that a thickened cell wall increases the path that vancomycin
has to travel, preventing the diffusion of vancomycin molecules from the environment to
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the cell’s active site, which is the tip of the division septum in the cytoplasmic membrane
(19, 20). This enables VISA and VRSA strains to continue synthesizing peptidoglycan
and to survive in a vancomycin-containing environment. Our results suggest that the
observed sensitivity of msaABCR operon mutants to vancomycin may be due to the
decrease in cell wall thickness.
As stated earlier, one of the key phenotypes of the msaABCR operon mutants is
the prolonged lag phase in the vancomycin-containing medium, which may also be due to
the thinning of the cell wall. A study comparing VSSA with VISA strains found that the
length of the lag phase negatively correlated with cell wall thickness (39, 41). It was
proposed that a thin cell wall binds vancomycin molecules at a significantly slower rate
than in the wild-type strains and therefore removes drug molecules from the medium at a
slower rate, which in turn results in a prolonged lag phase.
Indeed, we observed a three-fold decrease in the binding of vancomycin
molecules to the cell wall of the msaABCR mutants compared with the respective wildtype cells (Figure 3.6). To date, however, the mechanistic link between the length of the
lag phase and the thickness of the cell wall has not been defined.
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Figure 3.6. Vancomycin binding assay with wild types Mu50, HIP6297, and LIM2 and
their respective ∆msaABCR mutants, and complemented mutants. Vancomycin was added
to a growing culture of cells. After 1 hour, cells were harvested and supernatant medium
was dot blotted and detected with anti-vancomycin antibody. Figure shows that
∆msaABCR mutants bind significantly less vancomycin than the wild types.
The msaABCR operon regulates the expression of pbp4, sigB, and mprF in a straindependent manner
Studies with VISA strains have yielded descriptive assessments that correlate
various phenotypes with vancomycin intermediate resistance. Collectively, these studies
have resulted in a set of phenotypes that are commonly observed in VISA strains. Several
studies have also used a variety of approaches to identify specific genes that are
associated with vancomycin resistance. These include expression studies (e.g.,
microarray analysis) (47, 48, 73), and comparisons of isogenic resistant and sensitive
strains by targeted mutagenesis experiments (24, 45, 53, 59, 72, 82, 83). Collectively,
these studies have identified the following regulator genes as critical to intermediate
vancomycin resistance in S. aureus: pbp4, sigB, walKR, graS, graR, mprF, dltA, vraS,
vraR, and sarA.
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We examined the expression of these genes in the msaABCR operon mutants
using quantitative RT-PCR in the absence and presence of vancomycin. No significant
change in gene expression was observed for graR, graS, dltA, vraSR, and walkR in either
of the strains. However, we found that expression of pbp4 was increased and that of sigB
was decreased in the Mu50 msaABCR mutant and expression of mprF was decreased in
the HIP6297 msaABCR mutant (Figure 3.8 a-b).
The msaABCR mutant of Mu50, but not HIP6297, showed a three-fold increase in
pbp4 expression both in the presence and absence of vancomycin (Figure 3.8 a). We
confirmed the increase in the expression of PBP4 in the Mu50 msaABCR operon mutant
by performing a fluorescent penicillin-binding assay with Bocillin-FL to measure the
levels of PBP4 protein. We found that the Mu50 msaABCR operon mutant produces
6.003-fold higher levels of PBP4 compared with the wild type (Figure 3.7).

Figure 3.7. Fluorescent penicillin binding assay from purified cell membranes of wild
type Mu50, Mu50∆msaABCR mutant, and complemented mutants. Lower panel shows
the quantification graph of the gel.
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PBP4 is involved in cell wall biosynthesis as a DD-carboxypeptidase enzyme
(84). PBP4 is required for cleavage of the peptide bond of D-Ala-D-Ala residue of the
pentapeptide sidechain of undecaprenylphosphate-MurNAc-pentapeptide prior to crosslinking between the penultimate alanine and the third lysine of another NAM. Because
vancomycin binds to D-Ala-D-Ala residues, any vancomycin-bound residue becomes
unavailable for PBP4 and therefore cannot be used for crosslinking. VISA strains
produce significantly less PBP4 compared with the VSSA strains (42, 85). Deletion of
pbp4 in the VSSA strain N315 caused an increase in the vancomycin MIC, which was
restored by complementing pbp4, suggesting that the function of pbp4 is directly related
to the vancomycin MIC (42). Although the genetic regulation of pbp4 in VISA strains is
not yet understood, it has been proposed that reduced expression of PBP4 in VISA strains
results in an increase of intact D-Ala-D-Ala and consequently a build-up of uncrosslinked
muropeptide monomers in the cell wall. These monomers hinder the diffusion of
vancomycin molecules by attaching the drug molecules to the intact D-Ala-D-Ala
termini. The attached vancomycin molecules are thought to become part of the resistance
mechanism by sterically hindering additional vancomycin molecules during the diffusion
process (86). These findings indicate that there is a negative correlation between the
expression level of pbp4 and resistance to vancomycin. Hence, our results suggest that
the msaABCR operon negatively controls the expression of pbp4 in Mu50 and the
increased sensitivity of the Mu50 msaABCR mutant to vancomycin may be attributed to
the increased PBP4 activity. Further studies are needed to define the relationship between
the msaABCR operon, PBP4 activity, and the amount of crosslinks in the cell wall.
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Gram-positive bacteria respond to stress by expressing alternative sigma factors
such as sigma B (encoded by sigB). The presence of antibiotics, such as methicillin or
vancomycin, has been shown to activate the expression of sigma B in S. aureus,
implicating this factor in antibiotic resistance (72, 87, 88).
Expression of sigB was significantly reduced in the msaABCR mutant of the
Mu50 strain compared with the wild type in both the absence (4.91-fold) and presence of
vancomycin (7.15-fold). Expression of asp23, which is directly under the regulation of
sigB, was also down-regulated in Mu50. Interestingly, this change in expression was not
observed in strain HIP6297, indicating that this regulatory effect is strain dependent.
Mutation of sigB has been shown to reduce vancomycin resistance in a passage-derived
resistant strain of S. aureus (72). Conversely, activation or overexpression of sigB led to
thickening of the cell wall and increased vancomycin resistance in VSSA strain N315
(46, 49). Cell wall inhibitor antibiotics induce a stress response in S. aureus cells (63).
Resistant cells may have the capacity to respond to and counteract the stress more
efficiently than their sensitive counterparts. We propose that the msaABCR operon
mutant of Mu50, with decreased sigB expression, becomes more susceptible to stress
conditions including the presence of vancomycin in the medium. However, the
mechanism by which the msaABCR operon regulates sigB and the reason why this
regulation occurs in strain Mu50, but not in strain HIP6297, is currently unclear.
Another regulator, which is directly under the control of the stress response
system, mprF, was found to be significantly down-regulated in the msaABCR operon
deletion mutant of HIP6297 but not of Mu50. MprF is a putative trans-membrane protein
that mediates the biosynthesis of lysylphosphatidylglycerol (45). It is a positively charged
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phospholipid that contributes to a net positive charge on the cell surface. MprF-deficient
mutants have been shown to be sensitized to cationic antimicrobial peptides of the
immune system (89, 90) and vancomycin (45). This phenotype was attributed to the fact
that because MprF mediates the synthesis of a positively charged lipid, absence of it leads
to the accumulation of a net negative charge on the cell surface, which attracts cationic or
positively charged molecules including vancomycin. Ruzin et al. 2003 (45) showed that
an mprF mutant indeed binds more vancomycin to the membrane than its corresponding
wild type. This may be contributing to the increased susceptibility of the HIP6297
msaABCR operon deletion mutant to vancomycin.
The strain-dependent variations among VISA isolates, both in terms of phenotype
and genetic mutations, are not uncommon. Reduced vancomycin sensitivity has been
reported to be unstable for some isolates such as HIP5836 and Mu50 (91) but not in the
laboratory-derived passage-selected VISA strains such as BB270V15, COLV10, and
13136p−m+V20 (19). Cell wall thickening has been shown in most VISA isolates but to
varying degrees. For instance, the thickness of the cell wall in strains JH9 and JH14 (20)
appears to be many fold higher than that observed in strain Mu50. Reduced crosslinking
of the muropeptides appears to be correlated with the vancomycin MIC in many VISA
strains but not all (30). Boyle-Vavra et al. 2001 (30) demonstrated that a vancomycin
trapping hypothesis and a uniform cascade of genetic events might not explain the
resistance phenotype in every VISA strain isolated. However in this study, a
reorganization of the cell wall was found to be common among all VISA isolates. Nonamidated residues of glutamic acids have been shown to play a role in the resistance
mechanism of some, but not all, VISA strains (74). Similarly, many genes have been
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correlated with vancomycin resistance either in terms of altered expression or point
mutations, but none of these have been found to be present without exception. When
analyzing the results of multiple studies (24, 42, 47, 86), it appears that, although
theoretically lowered expression of PBP4 could be correlated with a higher vancomycin
MIC, the laboratory-derived VISA mutants do not follow this pattern.
Strain-dependent variations are also found in terms of mutations in response
regulator genes. Although mutations in genes such as vraSR, graSR, clpP, and walKR
have been correlated with a VISA phenotype, sequence analysis of these genes in 39
VISA isolates revealed that none of these mutations are universal among all VISA strains
(24). While 27 VISA strains possessed mutations in walK, only a few of these mutations
were at the same site in the gene. Similarly, three isolates harbored mutations in clpP,
four isolates had mutations in graR, and eight isolates had vraS mutations, but all of these
mutations were at different sites within the genes. Shoji et al. (2011) proposed that these
differences indicate the existence of alternative pathways in different VISA isolates for
the establishment of vancomycin resistance (24).
Strain-dependent variation has also been observed in the function of global
regulators in S. aureus. Zielinska et al. (2011) studied the regulatory role of sarA on the
alpha-toxin phenotype of laboratory and clinical strains of S. aureus, and observed that
sarA exerts a strain-dependent effect on the transcription of RNAIII and hla (92). Blevins
et al. (2002) also demonstrated a strain-dependent regulatory role for sarA and agr (93).
In this context, variations between strains Mu50 and HIP6297 would be expected. For
instance, Mu50 harbors one mutation in VraS (I5N) and one in GraR (N197S), HIP6297
possesses neither of these but possesses a mutation in WalK (A567D) (24). Although
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Mu50 and HIP6297 strains have been described to have inactivated PBP4 (86), our
results indicate that the msaABCR operon exerts a strain-dependent effect on pbp4
expression.
Strain variations in VISA isolates, such as the ones in this study, have made it
difficult to define a common mechanism to the establishment of the VISA phenotype. In
conclusion, we have shown that the msaABCR operon plays a key role in intermediate
vancomycin resistance and that its inactivation leads to homogeneous vancomycin
sensitivity despite strain differences.

Figure 3.8(a). Transcription profile of genes linked to vancomycin resistance in
Mu50∆msaABCR and complemented mutant compared to wild type.
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Figure 3.8(b). Transcription profile of genes linked to vancomycin resistance in
HIP6297∆msaABCR and complemented mutants in comparison to wild type.
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Table 3.1
Strains and Plasmids used in this study
Strains or Plasmids
Strains
E. coli
TOP10
S. aureus
Mu50
Mu50∆msaABCR
Mu50 comp.
HIP6297
HIP6297∆msaABCR
HIP6297 comp.
LIM2
LIM2∆msaABCR
LIM2 comp.
Plasmids
pKOR1
pKOR1- ∆msaABCR

pCN34

pHV1249
pCN34(Cmr)
pCN34(Cmr) - msaABCR
operon

Relevant feature

Reference or
Source

F−ϕ80lacZ∆M15 recA1

Life
Technologies

VISA, MRSA, mecA+Ermr, ST5
msaABCR operon knock out
Mu50∆msaABCR (pCN34-msaABCR operon)
VISA, mecA+, ST5
msaABCR operon knock out
HIP6297∆msaABCR (pCN34-msaABCR
operon)
VISA, mecA+, ST247
msaABCR operon knock out
LIM2∆msaABCR (pCN34-msaABCR operon)

NARSA
This study
This study
NARSA
This study
This study

AmprCmr ; Shuttle vector, temperature
sensitive
Upstream and downstream fragment of
msaABCR operon cloned into pKOR1 for
mutagenesis
Ampr Ermr ; Shuttle vector, Low copy number

Bae et al.,
2006
This study

Cmr ; 996-bp PCR fragment containing
cat194 gene cloned into pCN34 to generate
pCN34(Cmr)
AmprCmr ; used for trans - complementation
of msaABCR operon
1.7 kb PCR fragment containing msaABCR
operon cloned into pCN34(Cmr)

BEI Resources
This study
This study

Charpentier et
al., 2004;
NARSA
Petit et al.,
1990
This study
This study
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Table 3.2
Primers used in this study

Primers

Operon del 1
Operon del 2
Operon del 3
Operon del 4
Comp-F1
Comp-R1
Cm-F
Cm-R
sigB-F
sigB-R

Sequences (5’  3’)

GGGGACAAGTTTGTACAAAAAAGCAGGCTGCTTTAAATCAG
CGATTAATGTTCGTTTG
ATGACTGGATCCTATTAAAGACCCCTTCCATACTTCAAAAAC
ATGACTGGATCCTTTCATGATGCTTGTTTAAAGTGTGGTAT
GGGGACCACTTTGTACAAGAAAGCTGGGTAGTTTGGATTATC
AATTCAATATGGCTTAGC
GGGGGATCCTTTTACCACCTCATAATGTTAT
CCCGAATTCAAATAAACAAAGTAATCCCCGA
GTTTAAGGGCCCACCTAGGTATTATCAAGATAAGAAAGAAA
AG
CTATGACTCGAGGCCGCGGCCTTCTTCAACTAACGGGG
AAGTCCGGTACCACAGTATATAAAGAATCTGGTG
GGTTCCAGATCTAAATTCTATTTATGTGCTGC

RT-PCR Primers:
gyrB RT F
gyrB RT R
mprF RT F
mprF RT R
dltA RT F
dltA RT R
rnaIII RT F
rnaIII RT R
graR RT F
graR RT R
graS RT F
graS RT R
walKR RT F
walKR RT R
pbp4 RT F
pbp4 RT R
gyrA RT F
gyrA RT R
sigB RT F
sigB RT R

CAACTATGAAACATTACAGCAGCGT
TGTGGCATATCCTGAGTTATATTGAAT
GAACCACCGTTTTCAACTGAA
GTAAATCTAACTCTGGCAACCATC
ATGTTTAGCATCAGGCGGTAC
ACTTGGGAAACGGCTCACTAA
CTGAGTCCAAGGAAACTAACTCTAC
TGATTTCAATGGCACAAGAT
GTTGCTGGTATTGAAGATTTCG
CGCCAAGTTCCATACTCATCAC
CACCTGTGACAGCCATGAAATTA
CATCAATGACCATGCGTTTAAGTGACA
AAACAACTACAATCCCTTCATACTAA
CTTGACGGTTGGCATACTCACTTAA
CCGTTGGATTGACGAAATGT
ACCAGCGATTTCGTTGATTT
CATTGCCAGATGTTCGTGAC
CCGGTGTCATACCTTGTTCA
AACCGATACGCTCACCTGTC
CGCGAACGAGAAATCATACA
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Table 3.3
Vancomycin MIC of Wild types, msaABCR operon deletion mutants, and complemented
mutants

Strains

Vancomycin MIC (µg/ml)

Wild type
∆msaABCR
Complemented mutant (pCN34-msaABCR)

Mu50

HIP6297

LIM2

N315

6.25
1.56
3.13

6.25
1.56
3.13

6.25
1.56
3.13

1.56
1.56
1.56

Table 3.4
Cell wall thicknesses of wild types, msaABCR operon deletion mutants, and
complemented mutants

Strains

Mu50
HIP6297

Mean thickness of cell wall (nm ± SE)

Wild type

∆msaABCR

Complemented mutant
(pCN34-msaABCR)

50.83 ± 3.82
41.8 ± 2.65

24.23 ± .91
25.6 ± 1.61

44.5 ± 3.98
51.4 ± 2.63

nm = nanometer; SE = Standard error of mean
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CHAPTER IV
MOLECULAR AND PHENOTYPIC CHARACTERIZATION OF METHICILLINRESISTANT Staphylococcus aureus ISOLATES CAUSING BACTEREMIA AT A
MAJOR HOSPITAL IN SOUTHERN MISSISSIPPI
Abstract
Staphylococcus aureus is the predominant cause of bacteremia worldwide.
Distribution of methicillin-resistant Staphylococcus aureus (MRSA) tends to be
geographically unique. We assessed molecular epidemiology and antibiotic resistance of
MRSA isolates causing bacteremia in Southern Mississippi.
We collected 30 MRSA blood isolates over 1 year, which were subjected to
staphylococcal chromosomal cassette mec (SCCmec) typing, pulsed field gel
electrophoresis (PFGE), multilocus sequence typing (MLST), and antibiotic resistance
profiling. Risk factors underlying bacteremia were analyzed by Fisher’s exact test and
regression analysis.
All MRSA isolates were mecA positive and 70% were SCCmec type IV,
indicating community-acquired infections, and 30% were SCCmec type II, of which 50%
were Panton–Valentine leukocidin (PVL) negative, indicating hospital-acquired
infections. Most isolates (97%) were resistant to oxacillin and erythromycin and 30% to
clindamycin. Risk factor analysis revealed a strong association of prior hospitalization,
prior antibiotic usage, nursing home origin, and presence of PVL with MRSA isolates
with minimum inhibitory concentration (MIC) >1 µg/ml for vancomycin.
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Diverse genetic backgrounds in terms of SCCmec, PFGE, and MLST types of
MRSA were identified as causing bacteremia in Mississippi. A strong association of PVL
with high vancomycin MIC is one of the important findings of our study.
Introduction
Staphylococcus aureus is a major human pathogen responsible for both
community and hospital-associated infections. It is the causative agent of a wide array of
diseases from skin and soft tissue infections (SSTIs) to more life-threatening conditions
such as endocarditis, osteomyelitis, and septic arthritis. Methicillin-resistant
Staphylococcus aureus (MRSA) strains are causing increasingly complex public health
problems in both community and hospital settings. Initially, MRSA strains were largely
confined to hospitals and were referred to as hospital-acquired MRSA (HA-MRSA),
causing treatment difficulties, especially in patients with prior exposure to antibiotics.
During the past two decades, S. aureus infections have been worsened by the emergence
of community-acquired MRSA (CA-MRSA) (94). The United States has an epidemic
caused by CA-MRSA isolates (95-97). CA-MRSA isolates are clinically significant
because they can also cause severe disease in individuals who are apparently healthy and
without any predisposing risk factors (94, 97).
CA-MRSA isolates can be distinguished from HA-MRSA by molecular typing
tools. Although all the MRSA isolates carry staphylococcal chromosomal cassette mec
(SCCmec), the length of the SCCmec elements varies between CA- and HA-MRSA
isolates. HA-MRSA isolates typically carry SCCmec types I, II or III, which are longer in
size compared with types IV or V carried by CA-MRSA isolates. Additionally, HA-
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MRSA isolates do not typically carry Panton–Valentine leukocidin (PVL) genes (lukS-PV
and lukF-PV), whereas community-acquired isolates frequently carry PVL (94).
Bacteremia caused by MRSA isolates is associated with a higher risk of mortality
compared with methicillin-susceptible Staphylococcus aureus (MSSA) (98). Given the
importance of invasive MRSA infections in both community and healthcare settings, it is
imperative to understand the clonal variation among clinical isolates. Isolates belonging
to a certain clonal background have been shown to be more prevalent and virulent than
others (99). In the United States, pulsed field type USA300 has been the dominant strain
causing MRSA infections in community settings. Although studies by The Center for
Disease Control and Prevention (CDC) indicated that USA100 used to be the
predominant type causing clinical bacteremia, others reported that USA300 is becoming
more dominant even in hospital settings (100). Tenover et al. (100) studied the
prevalence of USA100 and USA300 isolates in nine geographical zones in the United
States. The results showed that USA100 is predominant in mountain (60%), west north
central (45%), east north central (50%) and New England (70%) regions. In contrast,
USA300 was found to be predominant in the Pacific (49%), west south central (79%),
South Atlantic (42%) and Mid-Atlantic (53%) regions. However, notably, there were no
data reported from the Southeast United States (Mississippi, Alabama, Tennessee and
Kentucky). As a result of this gap in the epidemiological data of MRSA isolates in this
area, we carried out the first ever molecular and phenotypic characterization of MRSA
isolates causing bacteremia in Southern Mississippi. A retrospective cohort study carried
out between October 1995 and December 2003 showed that patients with MRSA
bacteremia have more underlying diseases (P = 0.02), more severe sepsis in response to
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their infection (P < 0.01), and consequently a higher mortality rate (101). Clearly, MRSA
infection in blood indicates a more robust disease state. Therefore, it is important to study
blood isolates to understand the degree of virulence of the MRSA isolates causing the
epidemic.
The fact that relatively few antibiotics are available to treat MRSA infections has
made the treatment more expensive and difficult. For many years vancomycin has been
the drug of choice for MRSA infections. However, since the late 1990s, the situation has
been exacerbated by the emergence of vancomycin intermediate-resistant and resistant S.
aureus strains. Continued use of vancomycin has been shown to accelerate the
appearance of resistant sub-clones both in the laboratory (77) and in hospital settings (29,
36, 75). Hence, for effective treatment with vancomycin, early detection of underlying
risk factors that may be associated with the increased vancomycin resistance is important.
In this study, we isolated and collected 30 bacteremia-causing MRSA isolates, analyzed
their clonality by molecular methods, and assessed their antibiotic resistance profile. We
also analyzed the association of predisposing risk factors with the outcome of increased
vancomycin resistance in certain strains.
Materials and Methods
Research ethics
The study was approved by the Institutional Review Board of the University of
Southern Mississippi and the Forrest General Hospital. Based on the protocol used, a
waiver of informed consent was granted.
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Collection and maintenance of isolates
Clinical isolates of MRSA strains from patients were collected from the
microbiology laboratory of a large referral level II trauma hospital in Forrest County in
Southern Mississippi. Isolates were collected between March 2013 and February 2014.
Once an MRSA organism was isolated from a positive blood culture, two or three
colonies were suspended into the Prompt Inoculation System-D (Siemens Medical
Solutions, Malvern, PA, USA). This is a microdilution procedure for susceptibility
testing that helps to determine the standardized inoculum needed for MicroScan. The
suspension was inoculated onto the MicroScan Gram Positive panel (Siemens Medical
Solutions) and loaded onto the MicroScan instrument for incubation, followed by
addition of reagents, and reading of the panel. The following day, the panel was
processed and observed by an experienced technologist to confirm the result and purity of
the culture. Once the isolates were confirmed as MRSA, they were re-streaked and
maintained in DMSO stocks at –80°C. A database of information about the source of
infections was maintained using de-identifiers.
Identification of virulence factors: mecA, PVL and hlg
The presence of mecA, PVL and hlg in the MRSA isolates was tested using
polymerase chain reaction (PCR). Chromosomal DNA of the isolates was amplified with
the primers listed in Table 4.1. The presence of a band in agarose gel from the respective
PCR compared with a positive control indicates the presence of the gene.
Pulsed field gel electrophoresis (PFGE)
PFGE was performed as described previously (102). SmaI-digested chromosomal
DNA of the bacterial isolates was run on PFGE. Gel images were analyzed and a
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dendrogram was generated in Bionumerics (version 5.0.1, Applied Maths, Austin, TX,
USA) using 80% similarity cutoff. Banding patterns were compared with standard
banding patterns of known PFGE types of S. aureus determined by McDougal et al.
(102).
Multilocus sequence typing (MLST)
MLST of the MRSA isolates was performed as described previously (103). Seven
housekeeping genes were amplified and sequenced using the primers listed in Table 4.1.
Sequence data for each gene were individually analyzed to determine the sequence type
for isolates according to the criteria provided for S. aureus using the web-based tool
MLST (http://www.mlst.net).
SCCmec typing
SCCmec typing was performed as described by Ghaznavi-Rad et al. (104). A
multiplex PCR was performed using the chromosomal DNA of the isolates as a template
and a primer mastermix containing all the primers at a final concentration of 100 nM,
using a Qiagen Multiplex PCR kit (Qiagen, Valencia, CA, USA). The primers used for
SCCmec typing are listed in Table 4.1. The PCR product was run in 2.0% agarose gel.
SCCmec type of the isolates was determined by comparing the band pattern of the PCR
product with the standard pattern as described previously (104).
Antibiotic susceptibility testing
Antibiotic susceptibility of all isolates was tested in triplicate using the broth
microdilution method according to the Clinical and Laboratory Standards Institute
guidelines (64). Mueller–Hinton broth supplemented with 2% NaCl was used for all
broth microdilution experiments. Antibiotic-containing wells were inoculated with 5 ×
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105 CFU/ml bacteria (65). After overnight incubation at 35°C, wells were analyzed for
visible bacterial growth as exhibited by turbidity. The lowest concentration of antibiotic
that prevented bacterial growth was considered to be the minimum inhibitory
concentration (MIC). The antibiotics used in this study were vancomycin, oxacillin,
erythromycin, clindamycin, rifampin, amoxicillin/clavulanic acid (Augmentin),
trimethoprim/sulfamethoxazole (Bactrim), and linezolid. Isolates were considered
resistant or sensitive based on the antibiotic breakpoints given on DAILYMED
(dailymed.nlm.nih.gov).
Risk factor analysis
The medical records of all selected blood cultures positive for MRSA were
reviewed for the following variables: demographics (age, sex, race, and body mass
index); comorbidity (diabetes mellitus, chronic skin condition, chronic kidney disease,
chronic heart failure, obesity, immunosuppression, and HIV infection); invasive
procedures (surgery, dialysis, intravenous catheterization, and mechanical ventilation);
history (smoking, drug usage, prior hospitalization, and antibiotic usage); and source of
bacteremia.
Data analysis and statistical tests
For analysis of the collected data, SCCmec, PFGE and MLST types were
combined for each isolate. From the antimicrobial resistance data, the resistance pattern
of each isolate was determined. The combined molecular types were then cross-tabulated
with antimicrobial resistance patterns. Associations between molecular types and
resistance pattern, between MLST and PFGE types, and between SCCmec and PFGE
types were determined by Fisher’s exact test. A P value < 0.05 was considered
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significant. All statistical analyses were performed using SPSS version 20. Risk factors
were binary coded in SPSS. To measure the association between risk factors and
vancomycin MIC >1 µg/ml, a crude analysis was first performed by Fisher’s exact test.
This test was chosen over χ2 because of the small sample size. The factors that displayed
a P value < 0.2 were used to perform binary logistic regression to determine the odds
ratio (OR).
Results
Overview
During the period between March 2013 and February 2014, a total of 322 clinical
MRSA isolates were collected from a regional hospital in Southern Mississippi. Thirty
blood isolates were selected for this study. Among all the blood cultures in the hospital,
the incidence of MRSA infection was estimated to be 49 for every 10 000 patients. The
proportion of blood MRSA isolates was estimated to be 7.1% of all MRSA isolates.
Clinical and epidemiological data
The majority of patients (72%) had a history of previous antibiotic usage.
Regarding the source of infection, pneumonia was found to be the most common source
of bacteremia (28.5%), followed by osteomyelitis (17.8%), and dialysis catheter infection
(10.7%). Diabetes mellitus was found to be the most common comorbidity among the
patients (51.7%). Details of the demographic data are listed in Table 4.2.
Pulsed field types and multilocus sequence types
PFGE has been a valuable tool for investigating S. aureus outbreaks, especially in
hospitals because of its high resolving power (105-111). McDougal et al. (102) described
USA typing as a nomenclature system for PFGE typing of S. aureus isolates. They

50
identified eight distinct lineages (USA100–800) that incorporate both oxacillin-resistant
and -sensitive strains. Since then, USA types have been used to describe the
epidemiological spread of pathogenic S. aureus strains worldwide.
In the present study, using an 80% similarity cutoff, blood isolates of MRSA
belonged to two major clusters designated A and B (Figure 4.1). Cluster A was composed
of isolates with USA100 and USA800 types, whereas Cluster B was composed of
USA300 and USA700 type isolates. One isolate (USMFG160) was novel; however, it
appeared closest to USA800 isolates in the PFGE typing. Overall, USA300 was found to
be the most common pulsed field type (40%) among the bacteremia-causing MRSA
isolates. USA100, 700 and 800 accounted for 23.3, 20 and 13.3% of the isolates,
respectively (Figure 4.2 A).
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Figure 4.1. PFGE pattern and phylogenetic tree of the MRSA isolates
MLST is based on sequence analysis of seven housekeeping genes (arcC, aroE,
glpF, gmk, pta, tpi and yqiL) of S. aureus. It gives an indication of clonal evolution of
MRSA. Different sequences of these genes are assigned unique allele numbers.
Combination of all seven genes resulted in an allelic profile or sequence type. In the
present study, blood isolates of MRSA belonged to five distinct sequence types. Among
these, ST5 accounted for 40% of the isolates, constituting the largest group. ST8, ST72
and ST100 were found in 37, 20 and 3% of the isolates, respectively (Figure 4.2 B). One
isolate (USMFG95) was novel. McDougal et al. (102) have observed a strong association
between the PFGE and MLST types of MRSA isolates. They found that each pulsed field
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type could be assigned a unique MLST type such as USA100 and USA800 sharing ST5,
and USA300 and USA700 isolates were ST8 and ST72, respectively. Our results largely
reflected these findings. For example, all USA100 and USA800 isolates were found to be
ST5. All but one USA300 isolates were found to be ST8, and only one (USMFG100) was
determined to be ST100. All but one USA700 isolates were found to be ST72. There was
a strong association between MLST and PFGE types (P < 0.001) of the blood isolates of
MRSA.
SCCmec types of bacteremia isolates
The methicillin resistance of S. aureus is caused by the presence of the mecA gene
that encodes a 78-kDa penicillin-binding protein (PBP2a or PBP2′). Compared to other
PBPs, PBP2a has a lower affinity for β-lactam antibiotics. As a result, even in the
presence of these antibiotics, the peptidoglycan layer is not disrupted and the bacterium
survives (11, 12). The mecA gene is housed within the mec operon together with its
regulatory genes mecI and mecR1 (11). Since the first detection of the SCCmec element
from N315 in 1999, multiple mec types have been identified because of the
hypervariability of SCCmec elements. Nine SCCmec types (I–VIII and VT) have been
detected to date. These are distinguished by the ccr gene complex, which helps in
excision and insertion of SCCmec elements (13-15). Clones of unique SCCmec types
have driven the epidemic of MRSA worldwide. For instance, SCCmec type I was first
discovered in the United Kingdom in 1961 and spread around the world during the 1960s.
Following that in 1982, SCCmec type II was discovered in Japan and this clone also
spread worldwide. During the 1990s SCCmec type IV caused a global epidemic.
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Therefore, in addition to MLST and PFGE, SCCmec typing can reveal information
pertinent for epidemiological analysis of MRSA strains (12).
In our analysis, all blood isolates were found to possess the mecA gene (Table
4.3), and 67% of the isolates were found to carry SCCmec type IV by multiplex PCR
(Figure 4.2 C). All but one USA300 strains were mec type IV. This isolate was found to
be mec type II. All the USA700 and USA800 isolates also possessed mec type IV.
USA100 isolates were found exclusively to possess mec type II, which accounted for
29% of the blood isolates. Only one isolate, USMFG160, which was identified as novel
by PFGE, was found to possess mec type V (3%). A strong association was found
between the PFGE and SCCmec types of the blood isolates of MRSA (P < 0.001).
Frequency of PVL and hlg in bacteremia isolates
PVL is capable of lysing the cell membrane of human neutrophils. Although its
role in pathogenesis is controversial, PVL has been strongly associated with several CAMRSA infections (112-115). Naimi et al. (10) showed with a large number of MRSA
cases that while 77% of CA-MRSA possessed the PVL gene, only 6% of HA-MRSA
were positive for PVL. Despite its strong correlation with CA-MRSA, it is not clear
whether PVL contribute to the fitness or virulence of the CA-MRSA strains (94). HAMRSA strains are typically characterized by SCCmec type II and an absence of PVL.
Therefore, despite the controversy about its function, the presence or absence of PVL
genes may be important to determine if a particular isolate is community or hospital
acquired. Hemolysin gamma (γ) (hlg) gene is another virulence factor, which has a
sequence similarity with PVL genes and functions as two component cytotoxins.
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In our study, all USA300 strains were PVL positive (Table 4.3). USA100 strains
(SCCmec type II) were mostly found to be PVL negative, except for two isolates
(USMFG23 and 24). It is likely that USA100, SCCmec II, and PVL-negative strains are
HA-MRSA (17% of all isolates). About 50% of all USA700 and USA800 isolates were
found to be PVL positive, while the rest were PVL negative. All isolates were found to be
hlg positive (Table 4.3).
Antibiotic susceptibility analysis
All isolates in this study were found to be resistant to oxacillin and
amoxicillin/clavulanic acid. The majority of the isolates (93%) were resistant to
erythromycin followed by 30% resistant to clindamycin. All isolates were found to be
sensitive to vancomycin, rifampin, trimethoprim/sulfamethoxazole, and linezolid.
Although we did not find any vancomycin intermediate or resistant strains, we noted that
some isolates had higher MIC for vancomycin than others. Specifically, while 13 isolates
had MIC of 0.5 µg/mL, seven had MIC of 1 µg/mL, and 10 had MIC >1 µg/ml for
vancomycin (Table 4.4). Our antibiotic susceptibility analysis of blood isolates reflected
the susceptibility record maintained by the hospital in the period between January and
June 2013, which revealed that all MRSA isolates tested were resistant to oxacillin and
amoxicillin/clavulanic acid. Ninety-one percent were resistant to erythromycin, 30% to
clindamycin, and 1% to trimethoprim/sulfamethoxazole. All MRSA isolates were
sensitive to vancomycin and linezolid. There was no significant association between
antibiotic resistance patterns and combined molecular types (PFGE/MLST/SCCmec) of
strains (P = 0.140). In other words, antibiotic resistance patterns were distributed across
all different molecular types (Figure 4.2 D).
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Figure 4.2. A. Distribution of PFGE types among the isolates causing bacteremia in
Southern Mississippi; B. Distribution of MLST types among bacteremia-causing isolates;
C. Distribution of SCCmec types in bacteremia-causing MRSA isolates; D. Distribution
of resistance patterns among the different clonal variations of the bacteremia-causing
MRSA isolates.
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Risk factors
Vancomycin is the most frequently used drug in treating bacteremia caused by
MRSA. Most of the patients who developed bacteremia had a history of antibiotic usage
(Table 4.5). Moreover, as mentioned earlier, we found 10 isolates (33%) with MIC >1
µg/ml for vancomycin from our susceptibility analysis (Table 4.4). Among these, five
isolates showed MIC of 2 µg/ml. Repeated use of vancomycin gives rise to resistant subclones with increased MIC compared with that of susceptible strains, and results in more
complicated, life-threatening conditions (77). We aimed to identify any predisposing risk
factors associated with this phenomenon. A detailed review of the medical records of the
patients and statistical univariate analysis (crude analysis) revealed that several risk
factors were associated with MIC >1 µg/ml for vancomycin. Table 4.5 lists all the risk
factors analyzed in this study. The factors with P < 0.2 in the univariate analysis were
further analyzed by logistic regression to determine OR. The presence of the PVL gene
was strongly associated with vancomycin MIC >1 µg/mL (P = 0.01) and showed a high
OR in regression analysis. With the exception of smoking, all the other factors revealed
an OR >1. This suggests that the odds of having an MRSA isolate with vancomycin MIC
>1 µg/ml will increase in patients with prior usage of antibiotics, prior hospitalization,
coming from a nursing home, and being infected by a strain possessing PVL.
Discussion
To the best of our knowledge, this is the first study to assess systematically the
clinical and molecular epidemiology of bacteremia by MRSA isolates in Mississippi. The
hospital where the isolates were collected is a referral healthcare facility in Southern
Mississippi. Therefore, the patients are from a broad geographical area. Few studies of
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MRSA have been performed in Mississippi. A CDC study at a prison in Mississippi
revealed MRSA infections among 4.9% of the inmates. Among 59 cases tested, 41 were
confirmed MRSA by CDC (116). However, limited molecular analysis was done.
Our analysis showed that the majority of bacteremia cases were caused by
USA300-ST8-SCCmec IV isolates. This predominance of USA300 was observed in
studies done in other regions of the United States as well. Tenover et al. (100) analyzed
493 isolates from 23 US laboratories by PFGE typing. They found that USA300 was
predominant in the Pacific, west south central, South Atlantic and mid-Atlantic regions,
whereas in the mountain, west north central and east north central regions, USA100 was
predominant. However, the authors noted that the percentage of USA300 in the blood
isolates increased significantly compared with a previous study performed by CDCActive Bacterial Core surveillance (ABCs) in 2005–2006 with 1984 blood isolates. The
predominance of CA-MRSA over HA-MRSA in the hospital setting has been
mathematically modeled by D’Agata et al. (117). They predicted that CA-MRSA would
eventually become dominant in hospitals. An increasing community reservoir of CAMRSA strains results in a greater influx of CA-MRSA-infected patients into hospitals,
which contributes greatly to the dominance of CA-MRSA over HA-MRSA. Moreover,
CA-MRSA isolates carry smaller SCCmec genes, do not carry antibiotic resistance genes
unlike HA-MRSA strains, and grow more rapidly than HA-MRSA, which combined
gives CA-MRSA strains a competitive advantage and increased chance of colonizing, to
eventually outcompete HA-MRSA. Our observation from the hospitalized patients
confirms the predominance of USA300 isolates (CA-MRSA) in bacteremia-causing
isolates in our region.
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Although USA300 comprised the major portion of the isolates, regarding
antibiotic resistance, USA100-ST5-SCCmec II isolates were more resistant against
multiple drugs. Many of these isolates were PVL negative. USA300 isolates are typically
susceptible to fluoroquinolones and clindamycin (102). However, in this study, we found
that 30% of USA300 isolates were clindamycin resistant. This supports previous
observations in other studies that reported emerging resistance of USA300 isolates
against clindamycin (95, 118-120).
An important finding of our study was the strong association of the PVL genes
(lukS-PV and lukF-PV) with elevated MIC for vancomycin. In the univariate analysis of
association of risk factors, we found that prior antibiotic use (P = 0.03) and presence of
PVL (P = 0.01) had a strong association with vancomycin MIC >1 µg/ml. A high OR
(>1) in the regression analysis indicates that prior antibiotic use by a patient or presence
of PVL genes in an isolate increases the chance of vancomycin MIC >1 µg/ml. Prior
antibiotic use is known to be a leading cause of the emergence of vancomycin resistance
in a hospital setting (29, 36, 75). However, the contribution of PVL genes in the resistant
isolates is unclear. PVL is a leukocidin that is capable of killing human neutrophils by
lysing their cell membranes. Although it is regarded as a virulence factor for CA-MRSA
isolates, contradictory findings have been reported (112-115, 121). Voyich et al. (112)
and Wardenburg et al. (113) showed that the presence or absence of PVL did not affect
the capacity of a strain for sepsis formation or mortality rate in a mouse model. In
contrast, Labandeira-Ray et al. (114) showed overexpression of PVL caused necrotizing
pneumonia in a mouse model, suggesting that PVL contributes significantly to the
infection process of MRSA. Diep et al. (115) showed that PVL containing wild-type
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strains might possess a survival benefit in the early hours of infection over the PVLnegative mutants. Hongo et al. (121) showed that although PVL did not lyse mouse
neutrophils, anti-PVL antibodies were able to reduce the lysing activity of USA300 and
USA400 strains against human neutrophils, suggesting that PVL may be important for
CA-MRSA infection in humans, and that mice may not be suitable model for this study.
David et al. (94) pointed towards a variation in the amino acid sequence of PVL genes in
the MRSA strains to be the possible reason for these contradictory results. However, any
relation between the presence of PVL genes and vancomycin MIC has not been studied,
and further research is needed. Although it is unclear why PVL is strongly associated
with elevated vancomycin MIC, it may have been due to our relatively small sample size
of MRSA-infected patients, which may have resulted in skewed observation. Another
limitation of this study was that the isolates were collected from a group of ill individuals,
and less severely infected cases may have other risk factors that were not discovered in
this study.
In conclusion, to the best of our knowledge, this is the first report of systematic
molecular epidemiological analysis of MRSA isolates in Mississippi. Collectively our
data show the presence of both CA-MRSA and HA-MRSA isolates among bacteremiacausing MRSA in this region. The prevalence of USA300 isolates in a hospital setting is
an extension of a nationwide observation and mathematical prediction; however, the
association of PVL genes as a risk for vancomycin MIC warrants more detailed
investigation.

Table 4.1
Primers used in this study

Experiment

Primer name

Sequence (5’ to 3’)

Reference

SCCmec typing

Type I F
Type I R
Type II F
Type II R
Type III F
Type III R
Type IVa F
Type IVa R
Type IVb F
Type IVb R
Type IVc F
Type IVc R
Type IVd F
Type IVd R
Type IVh F
Type IVh R
Type V F
Type V R
SA442 F
SA442 R

GCTTTAAAGAGTGTCGTTACAGG
GTTCTCTCATAGTATGACGTCC
GATTACTTCAGAACCAGGTCAT
TAAACTGTGTCACACGATCCAT
CATTTGTGAAACACAGTACG
GTTATTGAGACTCCTAAAGC
GCCTTATTCGAAGAAACCG
CTACTCTTCTGAAAAGCGTCG
AGTACATTTTATCTTTGCGTA
AGTCATCTTCAATATGGAGAAAGTA
TCTATTCAATCGTTCTCGTATT
TCGTTGTCATTTAATTCTGAACT
AATTCACCCGTACCTGAGAA
AGAATGTGGTTATAAGATAGCTA
TTCCTCGTTTTTTCTGAACG
CAAACACTGATATTGTGTCG
GAACATTGTTACTTAAATGAGCG
TGAAAGTTGTACCCTTGACACC
AATCTTTGTCGGTACACGATATTCTTCACG
CGTAATGAGATTTCAGTAGATAATACAACA

Ghaznavi-Rad et al.(104)
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Table 4.1 (continued).

Experiment

Primer name

Sequence (5’ to 3’)

Reference

Multilocus
sequence typing

arcC-Up

TTGATTCACCAGCGCGTATTGTC

Enright et al.(103)

arcC-Dn
aroE-Up
aroE-Dn
glpF-Up
glpF-Dn
gmk-Up
gmk-Dn
pta-Up
pta-Dn
tpi-Up
tpi-Dn
yqiL-Up
yqiL-Dn
luk-PV-F
luk-PV-R
hlg-F
hlg-R
mecA-F
mecA-R

AGGTATCTGCTTCAATCAGCG
ATCGGAAATCCTATTTCACATTC
GGTGTTGTATTAATAACGATAT
CTAGGAACTGCAATCTTAATCC
TGGTAAAATCGCATGTCCAATTC
ATCGTTTTATCAGGACCATC
TCATTAACTACAACGTAATCGTA
GTTAAAATCGTATTACCTGAAGG
GACCCTTTTGTTGAAAAGCTTAA
TCGTTCATTCTGAACGTCGTGAA
TTTGCACCTTCTAACAATTGTAC
CAGCATACAGGACACCTATTGGC
CGTTGAGGAATCGATACTGGAAC
ATCATTAGGTAAAATGTCTGGACATGATCCA
GCATCAACTGTATTGGATAGCAAAAGC
GCCAATCCGTTATTAGAAAATGC
CCATAGACGTAGCAACGGAT
AAAATCGATGGTAAAGGTTGGC
AGTTCTGCAGTACCGGATTTGC

PCR of PVL
PCR of hlg
PCR of mecA
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Table 4.2
Demographic characteristics of patients with MRSA bacteremia

Characteristics
Gender
Male
Female
Age ≥ 65 years
Race
Caucasian
African American
Other
Service in First 48 hours
Intensive care unit
Other
Comorbidities
Diabetes mellitus
Chronic skin condition
Chronic kidney disease
Chronic heart failure
Obesity
BMI ≥ 30
Immunosuppression
HIV
Invasive procedures
Surgery
Dialysis
Intravenous catheter
Mechanical ventilation
History
Smoking
Injection drugs
Hospitalization
Prior antibiotic usage
Long term care facility
Source of bacteremia
Pneumonia
Osteomyelitis
Dialysis catheter and fistula related infection
Cellulitis
Central line infection
Septic arthritis
Uterine tract infection

N (valid %)

16 (55.2)
14 (44.8)
11 (39.3)
14 (48.3)
15 (53.5)
0 (0)
11 (37.9)
18 (62.1)
15 (51.7)
4 (13.8)
12 (41.4)
8 (26.7)
11 (36.7)
11 (36.7)
2 (6.9)
3 (12)
3 (10.3)
6 (20.7)
8 (26.7)
3 (10.3)
11 (37.9)
1 (3.4)
12 (41.4)
21 (72.4)
6 (20.7)
10 (35.7)
5 (17.8)
4 (14.3)
4 (14.3)
3 (10.7)
1 (3.6)
1 (3.6)
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Table 4.3
Percentage of PVL, mecA and hlg virulence factors of isolates belonging to each
combination type (PFGE-MLST-SCCmec)

Combination types

Presence or absence of virulence factors
PVL

100-ST5-II
300-ST8-II
300-ST8-IV
300-ST100-IV
700-ST72-IV
700-Novel-IV
800-ST5-II
800-ST5-IV
Novel-ST5-V

+
7%
3%
33%
3%
10%
3%
3%
3%

mecA
−
17%
7%
3%
7%
-

+
23%
3%
33%
3%
17%
3%
3%
10%
3%

Hlg
−
-

+
23%
3%
33%
3%
17%
3%
3%
10%
3%

Table 4.4
Number of isolates possessing different MIC for vancomycin
Vancomycin MIC (µg/ml)
0.5
1
1.5
2

Number of isolates (%)
13 (43.3%)
7 (23.3%)
5 (16.6%)
5 (16.6%)

−
-
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Table 4.5
Univariate (crude) analysis of the association between risk factors and MRSA isolates
with MIC >1 µg/mL for vancomycin

Variables

Fishers Exact test p
value

Age
Sex
Weight
Service in first 48 hours
Diabetes mellitus
Chronic kidney disease
Chronic heart failure
Obesity
BMI
Immunosuppression
Mechanical ventilation
HIV
Use of injection drug
Smoking
Prior antibiotic use
Prior Hospitalization
Prior surgery
Long term care facility
Dialysis
Intra-venous catheter
Nursing home
Positive MRSA culture
Positive nasal swab
Presence of PVL
Presence of HLG
SCCmec type
Clonal type
MLST type

1
0.45
1
1
0.42
0.23
0.38
0.69
0.69
1
1
1
0.31
0.09
0.03**
0.1*
1
0.33
0.33
0.2
0.07*
0.2
0.28
0.01**
0.33
0.47
0.38
0.27

* P values less than 0.2; ** P values less than 0.05
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CHAPTER V
STRUCTURAL AND FUNCTIONAL CHARACTERIZATION OF MsaB PROTEIN
Introduction
The msaABCR operon has been described to be consisting of four genes namely
msaA, msaB, msaC, and an antisense RNA msaR. Of these, msaA and msaC were found
to be non-coding RNA and only effector protein was found to be encoded by msaB (56).
The MsaB protein is believed to execute the regulatory function of the msaABCR operon
through its interaction with global regulators such as sarA, agr, sigB, and other genes.
MsaB protein (previously called CspA) is predicted to contain a cold shock DNA binding
domain (CSD) and bears homology to E. coli and B. subtilis cold shock proteins (CSPs).
Bacteria respond to abrupt decrease in temperature by changing the protein expression
patterns (21). Although expression of most cellular proteins decrease during the cold
stress, expression of cold shock proteins reaches its peak at this time. One of the first
proteins described to express under cold shock is the E. coli cold shock protein CspA
(22). Many more proteins have been discover afterwards, possessing homology to the
E.coli CspA protein. This includes Bacillus subtilis proteins CspB, CspC, and CspD
(122). Sequence alignment of CSPs from several different organisms revealed that they
possess a significant sequence homology with eukaryotic gene regulatory Y-box factors.
Y-box proteins are DNA binding proteins are known to regulate transcription and
translation (123). Although most CSPs are found to be expressed during cold shock,
CspE and CspC are found to express constitutively at normal growth conditions at 37°C.
Moreover, the constitutively expressed CSPs were thought to be regulating two major
stress response proteins of E. coli RpoS and UspA (23). Staphylococcus aureus possesses
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three CSP family proteins. All of them bears significant homology to the E. coli CspA.
Katzif et al in their studies have suggested that the S. aureus CspA (or MsaB) is involved
in the regulation of pigment production and susceptibility to antimicrobial peptide of
human cathepsin-G (124, 125). The ability of S. aureus to cause a wide array of
infections is due to its ability to evade or defend itself from host immune system (126).
During Invasion, S. aureus has the ability to sustain the response triggered by the host,
including the harmful reactive oxygen species (ROS) produced by neutrophils and
macrophages, which are key cells of the human innate immune system. A study by Liu et
al suggested that the golden pigment produced by S. aureus, called staphyloxanthin plays
a significant role in susceptibility of S. aureus to reactive oxygen species (ROS) and
neutrophil killing (127). In that study, the ∆crtMN mutants that is deficient in pigment
production was found to be more susceptible to killing by ROS and by neutrophil
phagocytosis. Therefore MsaB could be indirectly or directly linked to the immune
evasion processes during stressed conditions. Moreover, MsaB has also been found to be
playing significant role in biofilm formation, antibiotic resistance, small colony variance
formation, and capsule formation. These are thought to be the basis for S. aureus long
term survival and persistence inside the host. Sahukhal et al suggested that the
∆msaABCR operon mutant of the community–acquired MRSA strain USA300 is
defective in biofilm formation (128). In an unpublished study, I observed that whereas
wild type S. aureus strain Mu50 is able to produce small colony variants, the msaABCR
mutant of it is unable to produce small colonies. These observations indicate that
msaABCR mutant may be defective in the stress response regulation. As mentioned
before, MsaB is found to be the only protein produced from the msaABCR operon, this
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suggests that MsaB may be responsible for stress response regulation in S. aureus.
aureus In this
study, we expressed and purified MsaB protein and characterized the structure and its
role in responding to stress conditions.
Materials and Methods
Cloning, expression,, and purification of the MsaB protein
The msaB open reading frame of S.aureus strain USA300-LAC was cloned into
pH6HTNHis6HaloTag® T7 plasmid (Promega Corporation, Madison, WI) as an XbaIApaI fragment. The resulting plasmid pH6HTN
pH6HTN-msaB was then transformed into E. coli
BL21-DE3
DE3 strain and transformants were selected in LB
LB-agar
agar plate with ampicillin. 10 ml
overnight culture of a positive col
colony was then inoculated into 1 Liter LB broth with 100
µg/ml ampicillin.

Figure 5.1. Plasmid map of pH6HTN His6HaloTag
When the cells reach OD600 = 0.4, Protein expression was induced by adding
isopropyl-β-D-1-thiogalactopyranoside
thiogalactopyranoside (IPTG) at a final concentration of 0.5 mM. 5
hours post induction, the cells we
were
re pelleted, resuspended in PBS, pH 7.4, supplemented
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with protease inhibitor cocktail (Roche), and lysed by sonication. Cell lysate was then
centrifuged at 10,000 ×g for 30 minutes to remove cell debris.
The His6Halo-MsaB fusion protein was purified from the clear lysate using a
nickel column (HisPurTM Ni-NTA resin, Thermo Scientific, Rockford, IL). The fusion
protein was eluted from the column with phosphate buffered saline supplemented with
250 mM imidazole. Imidazole was removed from the protein sample by dialyzing it
against pure PBS for overnight. The fusion protein was then cleaved using tobacco etch
virus (TEV) protease (AcTEV Plus, Life Technologies) to remove the His6Halo tag. 1
unit of the enzyme was used for 10 µg of protein. 20% glycerol was added to the
cleavage reaction to stabilize the protein. The cleavage reaction was carried out in 4°C
for overnight.
Finally, MsaB protein was purified from the tag using reversed phase HPLC. A
C-18 column was used for HPLC. The column was first activated by washing with 100%
acetonitrile (Acn) supplemented with 0.01% trifluoroacetotic acid (TFA). After
equilibrating the column with 100% H2O supplemented with 0.01% TFA, sample (1 ml)
was applied to the column at a rate of 1 ml/minute. The column was then washed/eluted
with a gradient of acetonitrile as follows: 0 – 2% Acn in 2 mins; 2 – 30% in next 2 mins;
30 – 70% Acn in next 12 mins; 70 – 100% Acn for next 2 mins, and finally, 100% acn for
2 mins. 1 ml fractions were collected throughout the process. Fractions that showed sharp
peaks at 280 nm were collected and analyzed by polyacrylamide gel electrophoresis.
MsaB fraction was determined by molecular weight and mass–spectrometry. After
removal of acetonitrile from the correct fraction by vacuum centrifuging, the protein was
dissolved in Tris-HCl buffer pH 7.4 and stored in -80°C for future use.
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Antibody against MsaB was raised in rabbit using a commercial source (Pierce
Biotechnologies, USA). A 70 – Day bleed of the animals immunized with MsaB was
purified by column chromatography to isolate pure anti–MsaB antibody.
Circular Dichroism of MsaB
Far-UV CD spectra of MsaB were collected on a Jasco J-815 CD spectropolarimeter using a 0.1 mm path length quartz cuvette (Precision cell). The samples were
monitored in a continuous scan mode from 260 to 198 nm with a scanning speed of 50
nm/min, with a data integration time of 8 s and with 1 nm bandwidth, while the data pitch
was maintained at 0.1 nm. For each data set, 12 scans were averaged and were subjected
to buffer subtraction. The buffer-corrected scans were then smoothened using the
Savitzky-Golay algorithm with the convolution width of 25 using the Jasco spectrum
analysis program.
Matrix–Assisted Laser Desorption/Ionization — Time of Flight (MALDI-ToF) analysis of
MsaB
The MsaB protein sample was analyzed using MALDI-ToF mass spectrometer
(Bruker Daltonics Inc). The sample containing 40 picomoles of MsaB (1 µL) was mixed
with 1 µL of matrix made of 10 mg sinnapinic acid (SA) dissolved in 1:1 acetonitrile:
water and 0.1% TFA. A 1 µL aliquot of this mixture was then spotted in triplicates on to
a MSP 96 microchip target (Bruker) and was air-dried. The sample was then analyzed on
the mass spectrometer with a laser intensity and detector gain kept constant at 60% laser
and 3x, respectively. The raw spectra were exported as an ‘.ascii’ file and plotted using
Origin 8.5 software.
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Western blot of MsaB
To measure the expression level of MsaB across the growth phases, quantitative
western blot was performed with whole cell lysates. Overnight cultures were normalized
to OD600= 0.05 and incubated at 37°C. Cells were harvested at OD600 = 0.7 (early), 1.5
(mid), 4.0 (late) and overnight (Post) points and frozen until used. Pellets were
resuspended in PBS with protease inhibitor and lysed by bead beating. Crude lysates
were centrifuged to remove the cell debris. Clear supernatants were collected and protein
concentrations in them were determined by BCA method using PierceTM BCA protein
assay kit (Life technologies, Grand Island, USA). 25 µg of proteins from each sample
was loaded in SDS-Polyacrylamide gel and separated. After proteins were blotted to a
PVDF membrane, and blocked by 5% non-fat skim milk, MsaB was detected by antiMsaB antibody and peroxidase conjugated secondary antibody. MsaB bands were
quantified in ImageJ software (67).
Stress Survival Assay
Survival capability of S. aureus during stress conditions was measured by
enumerating the colony-forming units (CFUs) in different stress conditions. Briefly,
overnight cultures were normalized to OD600= 0.05 and incubated at 37°C in TSB for 2
hours. Cells were collected by centrifugation and the spent media was discarded. Cells
were then resuspended in either plain TSB as a control, or stress conditions such as, low
pH (5.5), Saline condition (100 mM NaCl), and oxidative stress (10 mM H2O2). Cells
were then incubated at 37°C. A sample of the cultures were collected every two hours,
serially diluted, and spread on plain TSA plates. Next day, colonies were counted and
plotted in logarithmic scale using GraphPad Prism software.
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RNA extraction, reverse transcription, and qRT-PCR
An aliquot of an overnight culture was normalized to OD600 = 0.05 and grown to
exponential phase. At this time, cells were subjected to either plain TSB or stress
conditions such as, low pH (pH 5.0); saline stress; or 10 mM H2O2. Cells were grown for
1 h and harvested by centrifugation. The bacterial pellet was treated with RNAprotectTM
Bacteria Reagent (Qiagen, Valencia, CA, USA) and stored at −80°C until used. RNA
from the cell pellet was isolated using the RNeasy® mini kit (Qiagen) and dissolved in
DEPC-treated H2O. RNA quality was analyzed by determining the A260/280 ratio using a
nanodrop spectrophotometer (Thermo). Reverse transcription was carried out from 1000
ng of RNA using the iScriptTM cDNA synthesis kit (Bio-Rad Laboratories, Hercules, CA,
USA) according to the manufacturer’s instructions. Real-time PCRs were performed in
triplicate using the primers listed in table 5.1. The fold change in gene expression was
calculated using the formula 2-∆∆ct (68), using the gyrA gene as an internal control. Fold
change values were statistically analyzed by the independent sample t test using
GraphPad prism software.
Results
MsaB exists as a dimer in solution
Recombinant His6Halo-MsaB protein was purified by Nickel column using 250
mM imidazole as eluting agent. Upon analysis by PAGE, this protein appeared as a 42
kDa protein. Upon cleavage by TEV protease, a bigger fragment of 35 kDa and a smaller
fragment of 15 kDa appeared in gel (Figure 5.2 A). Albeit in a very low quantity, the
original 42 kDa protein also was found in the gel. The 35 kDa protein was predicted to be
the His6Halo tag based on bioinformatic analysis of its expected molecular weight (MW).
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The smaller band was expected to be MsaB, however its molecular weight appeared to be
exactly twice as much (15 kDa) as the predicted molecular weight of MsaB (7.5 kDa).
This band was excised and analyzed by mass-spectrometry using a commercial source.
Indeed, this protein was identified to be MsaB. To my surprise, MsaB appeared in gel as
a dimeric protein, and was found to be resistant to boiling and detergent treatment.
Therefore I hypothesized that MsaB exists as a dimer in solution. In HPLC
chromatogram, fractions 7–8; 11; and 14–15 showed sharp peaks at 280 nm (Figure 5.2
B). These fractions were collected and analyzed in PAGE. Among these, Fraction 11 was
found to be the 15 kDa protein, hence MsaB (Figure 5.2 C, D). After removal of
acetonitrile removal, MsaB was dissolved in 25 mM Tris-HCl buffer, pH 7.4. As
mentioned before, msaB ORF was cloned into the expression vector
pH6HTNHis6HaloTag® T7 plasmid, which has a TEV protease cleavage site between the
tag sequence and the msaB sequence. However, even after cleavage, MsaB carries over a
small remnant of the vector sequence, which makes the molecular weight of recombinant
MsaB precisely to be 9.2 kDa. Indeed, MALDI-ToF spectrum for MsaB revealed a peak
at 9218.69 Da, which corresponds to the monomeric MsaB. However MALDI-ToF also
revealed multiple peaks at 18447.85, 27643.53, and 36771.02 Da correspond to dimeric,
trimeric, and tetrameric MsaB protein, respectively (Figure 5.2 E). The decreasing
intensities of the multimeric peaks is likely due to the diminished ability of the higher
order multimers to fly from the matrix. These peaks corresponding to multimers may
also indicate that they are non-covalent oligomers of MsaB as indicated by the SDSPAGE analysis. However, since dimer was found to be the only visible species in
polyacrylamide gel, it suggests that MsaB predominantly exists in dimeric form in
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solution, however monomeric, trimeric, and tetrameric species can also exist although in
a very low quantities.

Figure 5.2. Expression, purification, cleavage, HPLC purification and MALDI-ToF
analysis of MsaB protein: PAGE (A & C), Western blot (D), and MALDI-ToF (E)
reveals that MsaB exists as predominantly dimeric species in solution.
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MsaB consists of predominantly α – helical conformation in solution
The secondary structure of recombinant MsaB was analyzed using far-UV
circular dichroism (CD). The spectrum showed that the protein adopted a α-helical
conformation with a signature negative minimum at 208 nm and a shoulder at 222 nm
(Figure 5.3). Given the expected transcriptional regulator activity of MsaB, it is not
surprising to observe this conformation, as most DNA binding protein regulators form αhelix, as they bind and regulate gene expression via the classical helix-turn-helix motif
(129, 130).

Figure 5.3. Circular Dichroism spectrum reveals that MsaB adopts an alpha-helical
structure in solution.
MsaB exists as a dimer in vivo and its expression is temporally regulated
Our results of analysis of MsaB in solution suggest that MsaB perhaps exists as a
dimeric species. However, whether this was an effect of a reagent or any artificial
condition on MsaB’s structure, was not clear. To eliminate this possibility, I examined
the molecular weight of MsaB from whole cell lysates of two S. aureus strains – Mu50
and UAMS-1 by western blot using anti-MsaB antibody throughout the different phases
of growth. Western blot of the MsaB protein in the early, mid, late, and post–exponential
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phases of growth revealed that MsaB indeed exists as a dimer in vivo as well (Figure
4.4).. Western blot also suggests that although MsaB is expressed in all phases of growth
in both Mu50
u50 and UAMS
UAMS-1, itss expression level decreases over time and is expressed less
in the late and post phases of growth compared to the early phases
phases.

Figure 5.4. Western blot of MsaB at different growth phases in Mu50 and UAMS-1
UAMS
Expression of msaB is up
up-regulated during stress conditions:
As hypothesized before, that MsaB, being a CspA family protein may be involved
in stress regulation in S. aureus. Real time PCR with RNA isolated from cells subjected
to stress conditions revealed that the expression oof msaB gene is up regulated 2.5 fold in
oxidative stress (H2O2), 4.5 fold in vancomycin stress, and 3 fold in low pH. However in
saline stress, no change in expression of msaB was noticed. These results suggest that
MsaB may indeed be involved in stress response regulation in S. aureus.
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Figure 5.5. RT-qPCR revealed that msaB is upregulated during stress condition.
msaABCR mutant has altered expression of RNA – polymearase subunits
I previously reported that Sigma B (σB), which is an important component of S.
aureus RNA polymersase, is down-regulated in the msaABCR mutant of the VISA strain
Mu50 (131).

Figure 5.6. STRING analyses revealed that MsaB is closely linked to RNA polymerase
subunits.
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Similar observation was also done by others (56) in the strain USA300 LAC. RNA
polymerases have been known to be responsible for altering global expression of genes
during stress conditions (23, 132). It has been reported that cold shock family protein
CspC regulates an RNA polymerase subunit RpoS in E. coli to regulate stress response
(23). Moreover from bioinformatic prediction analysis performed in the web based tool
STRING (http://string-db.org/), MsaB was found to be closely linked to RpoA, RpoB,
RpoC, RpoZ, and SigmaB (Figure 5.6). Hence I tested the transcription level of rpoA,
rpoB, rpoC, and rpoZ in wild type and msaABCR mutants, in both plain and stress
conditions. qRT-PCR analysis revealed that wild type and msaABCR mutant has
drastically different expression pattern of rpo genes. For instance, rpoZ is severely
downregulated in saline stress in the mutant, whereas its expression is unchanged in the
wild type. Also, rpoA is drastically downregulated in low pH in the wild type, but
relatively unchanged in the mutant. Moreover rpoB, rpoC, and rpoZ are all upregulated in
both oxidative stress and vancomycin stress, however they are relatively unresponsive to
these conditions in the mutant (Figure 5.7).
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Figure 5.7. qRT-PCR of rpo genes revealed a differential expression pattern between the
wild type and the msaABCR mutant during different stress conditions
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Discussion
MsaB, being a cold shock family protein, was hypothesized to be a stress
response regulator protein in S. aureus. In this part of my study, I investigated the
molecular structure of MsaB protein and its possible role of MsaB in stress response
regulation. To my knowledge this is the first study to systematically characterize the
structure and function of MsaB protein in S. aureus. Biophysical analysis of MsaB and
polyacrylamide gel electrophoresis revealed that it exists primarily as dimeric species in
solution. The reason for the multimeric nature of the MsaB protein is not clear at the
moment. Most DNA binding proteins have been found to dimerize at the binding site,
however they usually do not produce dimer in solution (133). MsaB was found to
produce a strong dimer which is resistant to SDS denaturation. The reason behind this is
also unclear and experiments are underway to investigate this phenomenon. Another
interesting fact that was revealed in the biophysical analysis is that MsaB has a
predominantly α-helical structure in solution. This is contrasting to most of the cold
shock family proteins that are composed of mostly anti-parallel β-sheets. Three –
dimensional structure of E. coli CspA, Bacillus subtilis–, B. caldolyticus–, and
Thermotoga maritime– CspB all revealed presence of five anti-parallel β-strands that
form a β-barrel (134). Moreover many other proteins that carry cold shock domains
possess the same β-barrel structure. The eukaryotic Y-box proteins, that also contain this
barrel structure has also been shown to be DNA/RNA binding protein. Many of these
cold shock proteins bind to single stranded DNA (ssDNA) or RNA (ssRNA). The only
exception is eukaryotic Clah8, which can bind to double-stranded DNA (dsDNA). In a
parallel study in our laboratory my colleague discovered that MsaB is able to bind
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dsDNA and consequently regulates the transcription of the target gene. This data suggests
that MsaB also has dsDNA binding properties like eukaryotic Clah8 protein. Our
observation of MsaB possessing predominantly α-helix suggests that MsaB may be a
member of helix-turn-helix DNA binding protein family rather than conventional β-barrel
possessing cold shock proteins. Later in this study, MsaB protein was also found to be
involved in stress response in S. aureus. msaB gene was found to be upregulated in all
tested stress conditions except saline. This suggests msaB may be an essential gene to
regulate transcription of other genes during the stress. Cold shock proteins are known to
regulate sigma factors. In the chapter II, in my study with vancomycin resistance, it was
found that sigma B gene was significantly down-regulated in the msaABCR mutant of
VISA strain Mu50. Also, our observation of alteration in expression of rpo genes suggest
that MsaB might be regulating the transcription of the RNA polymerase subunits
including sigma factors to modulate global gene expression in S. aureus. Further
investigation such as chromatin immune-precipitation (ChIP) coupled with high
throughput sequencing (ChIP-Seq) using anti MsaB antibody, is currently being carried
out to unravel which promoters MsaB binds to, in a global level to prepare the cells for
survival during stress conditions such as the presence of antibiotic, peroxide, or low pH.
Our earlier observations of defective biofilm, defective capsule, and defective antibiotic
resistance in the msaABCR mutant may all be the result of absence of regulation of RNA
polymerases by MsaB protein during these stress conditions. However more detailed
investigations are required to pinpoint the role of MsaB protein in survival during the
stress situations.
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Table 5.1
Primers used in this study

Experiment

Primer name

Sequence (5’ to 3’)

qRT-PCR

msaB RT F
msaB RT R
rpoA RT F
rpoA RT R
rpoB RT F
rpoB RT R
rpoC RT F
rpoC RT R
rpoZ RT F
rpoZ RT R

CGTATTCGTACATTTTTCAGCAA
CGGTCGCCTTCAACTACTTC
AATTGGTGTAATCCCTGTTG
ACCATTAGTCCAAACATCCA
AAACAGCGAAGTGTTTGAAT
GTACGACCTTCATCATCGTT
CGCGACTGAAAGCTACTTAT
GAACCATAACCTCAACGTGT
AAATTGATGAACAACCTGAAA
TACCGTCAGCAATTTCTTCT
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